Annotated References

Annotated Reference

• AARONSON SA: Growth factors and cancer. Science(1991) 254: 1146–1153.
   PubMed Web of Science ®Google Scholar
• ABRAHAM E, BURSTEN SL, SHENKAR R, ALLBEE J,SCHWARTZ M, WOODSON P, SINGER JW, REPINE JE: Inhibition of phosphatidic acid generation by CT-1501R Inhibits cytokine expression and prevents acute lung Injury in mice subjected to hemorrhagic shock. Clin.Res. (1994) 42: 146A. (Abstract).
   Google Scholar
• ADNANE J, GAUDRAY P, DIONNE CA, CRUMLEY G, JAYE M, SCHLESSINGER JJEANTEUR P, BIRNBAUM D, THEILLET C: BEIC and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast can-cers. Oncogene (1991) 6:659–663.
   PubMed Web of Science ®Google Scholar
• AGAH R, MALLOY B, SHEFtROD A, MAZUMDER A: Success-ful therapy of natural killer resistant pulmonary metas-tases by the synergism of gamma-interferon with tumor necrosis factor and interleukin-2 in mice. Cancer Res. (1988) 48:2245–2248.
   PubMed Web of Science ®Google Scholar
• AGUET M, MOGENSEN KE: Interferon receptors. In: In- te,feron 3. Gresser I (Ed) New York Academic Press, 1983 p1–22,.
   Google Scholar
• AKERLUND M, STROMBERG P, HAUKSSON A: Inhibition of uterine contractions of premature labour with an oxytocin analogue. Results from a pilot study. Br. J. Obstet. Gynaecol. (1987) 94:1040–1044.
   PubMed Web of Science ®Google Scholar
• ALEXANDER HR, DOHERTY GM, BURESH CM, VENZON DJ, NORTON JA: A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endo-toxin in mice. J.ExpMed. (1991) 173: 1029–1032.
   Web of Science ®Google Scholar
• ALLBERT JR, WISE CA, LOU CH, GOOKIN KS, PARMENTER MA, MORRISON JC: Subcutaneous tocolytic infusion therapy for patients at very high risk for preterm birth. J. Perinatol. (1992) 12:28–31.
   PubMedGoogle Scholar
• Study about the possibility of parenteral tocolytic therapy on an ambulatory basis.
   Google Scholar
• ANAFI M, GAZIT A, GILON C, BENNERIAH Y, LEVITZKI A: Tyrphostin-induced differentiation of mouse erythroleuketnia cells. FEBS Lett. (1993) 330:260–264.
   PubMed Web of Science ®Google Scholar
• ANAFI M, GAZIT A, ZEHAVI A, BENNERIAH Y, LEVITZKI A: Tyrphostin-induced inhibition of p210(ber-ab/) tyro-sine kinase activity induces 1(562 to differentiate. Blood (1993) 82:3524–3529.
   PubMed Web of Science ®Google Scholar
• ANDERSEN LF, LYNDRUP J, AKERLUND M, MELIN P: Oxy- tocin receptor blockade: A new principle in the treat- ment of preterm labour. Am.J. Perinatol. (1989) 6:196-199. [27] and [28] are reports of clinical use of oxytocin antagonists.
   Google Scholar
• ANGEL I, NIDDAM R, LANGER SZ: Involvement of alpha- 2-adrenergic receptor subtypes in hyperglycemia. J. Pharmacol. Exp. Ther. (1990) 254:877–882.
   PubMed Web of Science ®Google Scholar
• ANGEL I, SCHOEMAKER H, ARBILLA S, GALZIN AM, BERRY C, NIDDAM R, PIMOULE C, SEVRIN M, WICK A, LANGER SZ: SL 84.0418: a novel, potent and selective alpha-2 adrenoceptor antagonist: In vitro pharmacological pro-file. J. Pharmacol. Exp. Ther. (1992) 263:1327–1333.
   Google Scholar
• ANGEL I, SCHOEMAKER H, DUVAL N, OBLIN A, SEVRIN M, LANGER SZ: SL 84.0418: a new alpha2-antagonist with anti-hyperglycaemic properties. Eur. J. Pharmacol. (1990) 183:990–991.
   Google Scholar
• First report of the anti-hyperglycaemic activity of a novel a2-antago-nist acting as an insulin secretagogue.
   Google Scholar
• APRILE JA, RUSSO M, PEPE MS, LOUGHRAN TP: Activationsignals leading to proliferation of normal and leukemic CD3+ large granular lymphocytes. Blood (1991) 78:1282–1285.
   PubMed Web of Science ®Google Scholar
• ARCH JRS, AINSWORTH AT, CAWTHORNE MA, PIERCY V,SENNITT MV, THODY YE, WILSON C, WILSON S: Atypical 13-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature (1984) 309:163–165.
   PubMed Web of Science ®Google Scholar
• ARIAD S, SEYMOUR L, BEZWODA WR: Platelet-derived growth factor (PDGF) in plasma of breast cancer pa-tients: correlation with stage and rate of progression. Breast Cancer Research and Treatment (1991) 20:11–17.
   PubMed Web of Science ®Google Scholar
• ARINAGA S, KARIMINE N, TAKAMUKA K, NANBARA S, AKIYOSHI T: Enhanced induction of LAIC activity after lentinan administration in patients with gastric carci-noma. Int. J. Immunopharmacol. (1992) 14:535–539.
   PubMed Web of Science ®Google Scholar
• ARTEAGA CL, HANAUSKE AR, CLARK GM, OSBORNE CK,HAZARIKA P, PARDUE RI, 110 F, VON HOFF DD: Im-munoreactive alpha-transforming growth factor activ-ity in effusions from cancer patients as a marker of tumor burden and patient prognosis. Cancer Res. (1988) 48:5023–5028.
   PubMed Web of Science ®Google Scholar
• ASHCROFf FM, ASHCROFT SJH: Properties and functionsof ATP-sensitive potassium channels. Cell Signalling (1990) 2:197–214.
   PubMed Web of Science ®Google Scholar
• ASHIZAWA K, WISHART GJ: Resolution of the sperm motility stimulating principle of fowl seminal plasma Into Ca2+. j Rep rod. Fert. (1987) 81:495–499.
   PubMedGoogle Scholar
• ASHWORTH RJ, COCKLE SM: The TRH-related peptide pyroglutamyl-glutamylprolinamide: a possible autocrine or paracrine modulator of pituitary function? In: Program and Abstracts, 74th Annual Meeting of the American Endocrine Society (1992) 677.
   Google Scholar
• ASHWORTH RJ, HAM J, COCKLE SM: The effects of pyro-glutamrylglutamyl prolineamide, a peptide related to thyrotrophin-releasing hormone, on rat anterior pitui-tary cells in culture. J. Endocrinol. (1994): In Press.
   Google Scholar
• ASHWORTH RJ, MORRELL JM, AITKEN A, PATEL Y, COCKLE SM: pG1u-Glu-ProNH2 is present in rat anterior and posterior pituitary gland. J. Endocrinol. (1991) 129:R1–R4.
   PubMed Web of Science ®Google Scholar
• ASHWORTH RJ, VISSER TJ, COCKLE SM: The TRH-like peptide pG1u-Glu-Pr0NH2 is present in porcine pitui-tary, but not in reproductive tissues. Biochem. Biophys. Res. Commun. (1991) 181:1557–1563.
   PubMed Web of Science ®Google Scholar
• ATZPODIEN J, KIRCHNER H, KORFER A, MENZEL T, SCHOMBURG A, POLIWODA H: Treatment of metastatic colorectal cancer patients with 5-fluorouracil in combi-nation with recombinant subcutaneous human inter-leukin-2 and interferon-alpha. Oncology In press.
   Google Scholar
• ATZPODIEN J, KIRCHNER H, LOPEZ-HANNINEN E, KOR-PER A, FENNER M, MENZEL T, DECKERT M, FRANZKE A, JONAS U, POLIWODA H: European studies of inter–673 53.
   Google Scholar
• Dleukin-2 in metastatic renal cell carcinoma. Sem. OncoL (1993) 20: 22–26.
   Web of Science ®Google Scholar
• ATZPODIEN J, KIRCHNER H, SCHOMBURG A, ET AL.: Outpatient chemo-immunotherapy of advanced malig-nant melanoma:sequential administration of sc inter-leukin-2 and interferon-alpha after iv dacarbazine and carboplatin. Europ. J. Cancer (1994) In press.
   Google Scholar
• ATZPODIEN J, KIRCHNER H: Cancer, cytokines, and cytotoxic cells: Interleulcin-2 in the immunotherapy of human neoplasms. Kiln Wochenschr (1990) 68:1–11.
   PubMedGoogle Scholar
• ATZPODIEN J, KIRCHNER H: The out-patient use of re-combinant human interieuldn-2 and interferon-alpha-2b in advanced malignancies. Europ. J. Cancer (1991) 27:88–92.
   PubMedGoogle Scholar
• ATZPODIEN J, KORFER A, EVERS P, FRANKS CR, KNOVER-HOPF J, LOPEZ-HANNINEN E, DALLMANN I, HADAM M, POLIWODA H, KIRCHNER H: Low-dose subcutaneous recombinant interleukin-2 in advanced human malig-nancy: A phase II outpatient study. MoL Biotb. (1990) 2:18–26.
   PubMedGoogle Scholar
• ATZPODIEN J, KORFER A, FRANKS CR, POLIWODA H, KIRCHNER H: Home therapy with recombinant inter-leukin-2 and interferon-alpha2b in advanced human malignandes. The Lancet (1990) 335:1509–1512.
   PubMed Web of Science ®Google Scholar
• ATZPODIEN J, SHIMAZAKI C, WISNIEWSKI D, GULATI S, BÜHRER CH, OZ S, LINK H, POLIWODA H, WELTE K, CLARKSON B: Interleukin-2 und interferon-alpha in der adoptoiven immuntherapie des plasmozytoms: em n ex-perlmentelles Modell. In: leukämien und Lymphome. Lutz D, Heinz R, Nowotny H, Stacher A et at (Eds) München, Wien, Baltimore, Urban & Schwarzenberg 1988, p211–212.
   Google Scholar
• BAARS JW, VAGSTAFF J, BOVEN E, VERMORKEN JB, VAN GROENINGEN CJ, SCHEPER RJ, FONK JCM, NIJMAN H'37, FRANKS CR, DAMSMA O, RINEDO HM: Phase I study on the sequential achninistration of recombinant human gamma-interferon and recombinant human inter-leukin-2 in patients with metastatic solid tumors. J. Natl. Cancer Institute (1991) 83:1408–1410.
   PubMed Web of Science ®Google Scholar
• BAILEY CJ, FLATT PR: Adrenoceptor-mediated control of glucose homeostasis in obese hyperglycaemic (ob/ob) mice. Diabetes Res. (1990) 14:87–91.
   PubMedGoogle Scholar
• BALLINARI D, CAPOLONGO L, BUZZEf 11 F, GRECO F,AMBOLDI N, MELEGARO G, BRASCA MG, GRANDI M, PENCO. S, TRIZIO D: 3-Arylidene-2-oxindoles: A new class of tyrosine kinase inhibitors: A structure/activity study. Proc. Am Assoc. Cancer Res. (1993) 34:387.
   Google Scholar
• BANERJI B, ALVING CR: Antibodies to liposomal phos-phatktylserine and phosphatidic add. Biochem.Cell Biol. (1990) 68: 96–101.
   PubMed Web of Science ®Google Scholar
• BARGMANN CI, WEINBERG RA: Oncogenic activation of the neu- encoded receptor protein by point mutation and deletion. EMBO (1988) 7:2043–2052.
   PubMed Web of Science ®Google Scholar
• BARKER AJ, DAVIES DH, BROWN DS, WOODBURN JR, GREEN LR, CARLIDGE SA, WAKELING. Structure activity relationships of 4-anilinoquinazolines as inhibitors of EGFR-tyrosine kinase activity. Ann. Oncol. (1994) 5:120.
   Google Scholar
• BARNEKOW A, PAUL E, SCHARTL M: Expression of the c-arc protoonocogene in human skin tumors. Cancer Res. (1987) 47:235–240.
   PubMed Web of Science ®Google Scholar
• BARTH N, GALAZICA A, RUDNICK 5: Lymphokines andcytokines. In: Principles of Cancer Biotherapy. Oldham R (Ed) New York (Raven) .1988, p273–290.
   Google Scholar
• BARTON CM, HALL PA, HUGHES CM, GULLICK WJ, LEMOINE NR: Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J. Path. (1991) 163:111–116.
   PubMed Web of Science ®Google Scholar
• BASH JA, ARROYO PA, WIEGAND G, QUINTANA L, WAL-LACK MK: Direct effects of alpha-interferon on murine adenocardnoma C-C 36 as a basis for synergy with interleukin-2 in cytolytic lymphocyte (CTL) mediated abrogiation of hepatic metastases. Proc. Amer. Assoc. Cancer Res. (1990) 31:251.
   Google Scholar
• BAULDRY SA, BASS DA, COUSART SL MCCALL CE: Tumornecrosis factor alpha priming of phospholipase D in human neutrophils. Correlation between phosphatidic add production and superoxide generation. Journal of Biological Chemistry (1991) 266: 4173–4179.
   Google Scholar
• BECKMANN MP, BETSHOLTZ C, HELDIN C-H, WESTER-MARK B, MARCO ED, DI FIORE PP, ROBBINS KC, AARON-SON SA: Comparison of biological properties and transforming potential of human PDGF-A and PDGF-B chains. Science (1988) 241:1346–1349.
   PubMed Web of Science ®Google Scholar
• BEJCEK BE, LI DY, DEUEL TF: Transformation by v-sis occurs by an internal autoactivation mechanism. Sci-ence (1989) 245:1496–1499.
   PubMed Web of Science ®Google Scholar
• BELLAVITE P, CORSO F, DUST S, GRZESKOWIAK M, DELLA BIANCA V, ROSSI F: Activation of NADPH-dependent superoxide production in plasma membrane extracts of pig neutrophils by phosphatidic add. J.Biol.Chem. (1988) 263: 8210–8214.
   PubMed Web of Science ®Google Scholar
• BELOSEVIC M, FINBLOOM DS, MELTZER MS, NACY CA: 11–2.
   Google Scholar
• A cofactor for induction of activated macrophage resistance to infection. j Immunol. (1990) 145:831–836.
   Google Scholar
• BERG G, ANDERSSON RGG, RYDEN G: Beta-adrenergic receptors in human myometrium during pregnancy: Changes in the number after beta-mimetic treatment. Am. J. Obstet. Gynecol. (1985) 151:392–396.
   PubMed Web of Science ®Google Scholar
• Important publication for the understanding of the `downregulation' during tocolytic treatment.
   Google Scholar
• BERG G, ANDERSSON RGG, RYDEN G: Effects of selective beta-adrenergic agonists on spontaneous contractions, cAMP levels and phosphodiesterase activity in myometrial strips from pregnant women treated with terbutaline. Gynecol. Obstet. Invest. (1982) 14:56–64
   PubMed Web of Science ®Google Scholar
• BERGMANN L, WEIDMANN E, BUNGERT B, HECHLER P, MITOU PS: Influence of various cytokines on the induc-tion of lymphokine-activated killer cells. Natl. Immunol. Cell. Growth Regulatory (1990) 9:265–273.
   PubMedGoogle Scholar
• BERGMANN I, WEIDMANN E, MITROU PS, RUNNE U, KEILHOLZ U, BARTSCH HH, FRANKS CR: Interleukin-2 in combination with interferon-alpha in dissemenated malignant melanoma and advanced renal cell carci-noma. Onkologie (1990) 13:137–140.
   PubMed Web of Science ®Google Scholar
• BERRIDGE TL, DOXEY JC, ROACH AG, SMITH CFC: Selec-tivity profile of the a2-adrenoceptor antagonist efaroxan in relation to plasma glucose and insulin levels in the rat. Eur. J. PharmacoL (1992) 213:205–212.
   PubMed Web of Science ®Google Scholar
• BERRIDGE 11, DOXEY JC, ROACH AG: Comparison of the effects of efaroxan and glibendamide on plasma glu-cose and insulin levels in rats. Eur. J. Pharmacol. (1992) 213:213–218.
   PubMed Web of Science ®Google Scholar
• Provides the first evidence that imidazolines and sulphonylureas can act synergistically to increase insulin secretion.
   Google Scholar
• BEUTLER B, MILSARK IW, CERAMI A: Passive immuniza- tion against cachectin/tumour necrosis factor protects mice from the lethal effect of endotoxin. Science (1985) 229: 869–871.
   PubMed Web of Science ®Google Scholar
• BEUTLER B: Tumor necrosis, cachesda, shock and in- flammation: a common mediator. Ann.Rev.Biochem. (1988) 57: 505–518.
   PubMed Web of Science ®Google Scholar
• BILDER GE, KRAWIEC JA, MCVETY K, GAZIT A, GILON C, LYALL R, ZILBERSTEIN A, LEVITZKI A, PERRONE MI-I, SCHREIBER AB: Tyrphostins Inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Amer. J. Physiol. (1991) 260:C721–C730.
   PubMed Web of Science ®Google Scholar
• BILEK R, GKONOS PJ, TAVIANINI MA, SMYTH DG, ROOS BA: The thyrotrophin-releasing (TRH)-like peptides in rat prostate are not formed by the expression of the TRH gene but are suppressed by thyroid hormones. J Endocrinol. (1992) 132:177–184.
   PubMed Web of Science ®Google Scholar
• BLACKMORE PF, BEEBE SJ, DANFORTH DR, ALEXANDERN: Progesterone and 17a-hydroxyprogesterone. Novel stimulators of calcium influx in human sperm. J. Biol. Chem. (1990) 265:1376–1380.
   Google Scholar
• BLAM SB, MITCHEL R, TISCHER E, RUBIN JS, SILVA M, SILVER S, FIDDES JC, ABRAHAM JA, AARONSON SA: Addi-tion of growth hormone secretion signal to basic fi-broblast growth factor results in cell transformation and secretion of aberrant forms of the protein. Onco-gene (1988) 3:129–136.
   Google Scholar
• SLAY JY, BERTOGLIO J, FRADELIZI D, CHOUAIB S: Func-tional interaction of IL-2 and TNF in the differentiation of LGL into LAK effectors. Intern.J. Cancer(1989) 44:598–604.
   PubMedGoogle Scholar
• BOLDT DH, MET S BJ, GEMLO BT, HOLDEN H, MIER J, PAIETTA E, MCMANNIS JD, ESCOBEDO LV, SNIECINSKI I, RAYNER AA, HAWKINS MJ, ATKINS MB, CIOBANU N, ELLIS TM: laboratory correlates of adoptive hrummotherapy with recombinant interleukin-2 and lymphikine-acti-vated killer cells in humans. Cancer Res. (1988) 48:4409–4416.
   PubMed Web of Science ®Google Scholar
• BOLEN JB, VEILLETTE A, SCHWARTZ AM, DESEAU V, ROSEN N: Analysis of pp60c-src in human colon carci-noma and normal human colon mucosal cells. Onco-gene Res. (1987) 1:149–168.
   PubMedGoogle Scholar
• BOLEN JB: Activation of pp60c-src protein kinase activ-ity in human colon carcinoma. Proc. Natl. Acad. Sci. USA (1987) 84:2251–2255.
   PubMed Web of Science ®Google Scholar
• BOLEN JB: Nonreceptor tyrosine protein kinases. Onco-gene (1993) 8:2025–2031.
   Google Scholar
• BORDEN EC: Augmented tumor-associated antigen ex-pression by interferon. J Natl. Cancer Institute (1988) 80:8–14.
   Google Scholar
• BOSSED, ADES E: Suppression of human immunoglobinsynthesis by interleukin-4 in tandem with interleukin-2 through large granular lymphocytes. Patho biology (1991) 59:391–395.
   Google Scholar
• BOUCHARD L, LAMARRE L, TREMBLAY PJ, JOLICOEUR P:Stochastic appearance of mammary tumors in trans-genic mice carrying the MMTV/c-neu oncogene. Cell (1989) 57:931–936.
   PubMed Web of Science ®Google Scholar
• BRAAKMAN E, VAN TUNEN A, MEAGER A, LUCAS CJ: 11-2and ifn-gamma enhanced natural cytotoxic activity: analysis of the role of different lymphoid subsets and Implications for activation routes. Cellular Immunol. (1986) 99:476–488.
   PubMed Web of Science ®Google Scholar
• BREM H, KIAGSBRUN M: The role of fibroblast growthfactors and related oncogenes in tumor growth. In: Oncogenes and Tumor Suppressor Genes in Human Malig-nancies. Benz CC, Liu ET (Eds), Kluwer Academic Publishers, Boston 1993 pps. 211–231.
   Google Scholar
• Review of FGF and its possible involvement in cancer.
   Google Scholar
• BRESLIN HJ, KUKLA MJ, TUMAN RW, REBARCHAK MC, BOWDEN CR: A novel series of N-(1-aminoalky-lidene)carboximidamides as potential hypoglycaemic agents. J. Med. Chem. (1993) 36:1597–1603.
   PubMed Web of Science ®Google Scholar
• BRICKELL PM: The p60c-src family of protein-tyrosine kinases: structure, regulation, and function. Crit. Rev. Ortcogen. (1992) 3:401–446.
   PubMedGoogle Scholar
• BROADSTONE VL, PFEIFER MA, BAJAJ V, STAGNER JI, SAMOLS E: a-adrenergic blockade improves glucose-po-tentiated insulin secretion in non-insulin dependent diabetes mellitus. Diabetes (1987) 36:932–937.
   PubMed Web of Science ®Google Scholar
• Evidence for enhanced sympathetic activity in NIDDM and illustrates the potential for use of a-adrenoceptor antagonists in management of NIDDM patients.
   Google Scholar
• BROOKS B, CHAPMAN K, LAWRY J, MEAGER A, REES RC: Suppression of lympholdne-activated killer cell induc-tion mediated by interleukin-4 transforming growth factor 01: Effect of addition of exogenous tumor ne-crosisfactor-alpha and interferon-gamma, and meas-urement of their endogenous production. Clin. Exp. Immunol. (1990) 82:583–589.
   PubMed Web of Science ®Google Scholar
• BROOKS CG, HOLSCHER M, URDAL D: Natural killer activity in cloned cytotoxic t lymphocytes: Regulation by interleukin-2, interferon, and specific antigen. J. Immunol. (1985) 135:1145–1152.
   PubMed Web of Science ®Google Scholar
• BROOKS CG, HOLSCHER M, URDAL D: Natural killer activity in cloned cytotoxic T Lymphocytes. Regulation by interleukin-2, interferon, and specific antigen. J Immunol. (1985) 135:1145–1152.
   Google Scholar
• BROUGHTON PIPKIN F, SYMONDS EM: Pregnancy-in-duced hypertension. In: Prostaglandins, and their inhibi-tors in clinical obstetrics and gynecology. Bygdeman M, Berger GS, Keith LG (Eds) MTP Press Ltd., Lancaster, 1986, p337–366.
   Google Scholar
• BROWN CA, LOWETH AC, SMITH SA, MORGAN NG: Stimu-lation of insulin secretion by imidazoline compounds Is not due to interaction with non-adrenoceptor ida-zoxan binding sites. Br.J. Pharmacol. (1993) 108:312–317.
   PubMed Web of Science ®Google Scholar
• BRUNDA MJ, BELLANTONI D, SULICH V: In vivo antitumoractivity of combinations of interferon-alpha and inter-leukin-2 in a murine model. Correlation of efficiacy with the induction of cytotoxic cells resembling natural killer cells. Intern. J. Cancer (1987) 40:365–371.
   Google Scholar
• BRUNDA MJ, ROSENBAUM D, STERN L: Inhibition of experimentally induced murine metastases by recom-binant alpha-interferon: on natural killer cell activity and inhibition of metastases. Intern. J. Cancer (1984) 24:421–426.
   Google Scholar
• BRUNDA MJ, TARNOWSKI D, DAVATELIS V: Interactionof recombinant interferons with recombinant inter-leukin-2: differential effects on natural killer cell activ-ity and interleukin-2-activated killer cells. Internatl. J. Cancer (1986) 37:787–793.
   PubMed Web of Science ®Google Scholar
• BRUNTON VG, WORKMAN P: Cell-signaling targets forantitumour drug development. Cancer Chemother. Phar-macol. (1993) 32:1–19.
   PubMed Web of Science ®Google Scholar
• Excellent review on the concept of targeting cell signaling compo-nents for cancer therapy.
   Google Scholar
• BRYCKAERT MC, ELDOR A, FONTENAY M, GAZIT A, OSHEROV N, GELON C, LEVITZKI A, TOBELEM G: Inhibi-tion of platelet-derived growth factor-induced mito-genesis and tyrosine kinase activity in cultured bone marrow fibroblasts by tyrphostIns. Exp. Cell Res. (1992) 199:255–261.
   PubMed Web of Science ®Google Scholar
• BUCHDUNGER E, TRINKS U, METT H, REGENASS U, MULLER M, MEYER T, MCGLYNN E, PINNA LA, TRAXLER P, LYDON NB: 4,5-Dianilinophthalimidie: A protein tyro-sine ldnase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc. Natl. Acad. Sci. USA (1994) 91:2334–2338.
   PubMed Web of Science ®Google Scholar
• Demonstrates and specific inhibition of EGF or erbB-2 receptors can produce antitumour effects in vivo.
   Google Scholar
• BUDD GT, OSGOOD B, BARNA B, BOYETT JM, FINKE J,MEDENDORP SV, MURTHY S, NOVAK C, SERGI J, TUBBS R, BUKOWSKI RM: Phase I clinical trials of interleukin-2 and alpha-interferon: Toxicity and immunologic ef-fects. Cancer Res. (1989) 49:6432–6436.
   PubMed Web of Science ®Google Scholar
• BUKOWSKI RM, MCIAIN D, OLENCKI T, BUDD GT, MUR- THY SA: Interleukin-2: use in solid tumors. Stem Cells (1993) 11:6–32.
   Google Scholar
• BUKOWSKI RM, MURTHY S, SERGI J, BUDD GT, MCKEEVER S, MEDENDORP SV, ZUBBS-GIBSON V, FINKE J: Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon alpha 2a. J. Biol. Modifiers (1990) 9:538–545.
   PubMedGoogle Scholar
• BURGUS R, DUNN TF, DESIDERIO D, WARD DN, VALE W,GURIFMAN R: Characterisation of ovine hypothalamic hypophysiotropic TSH-releasing factor. Nature (1970) 226:321-325. [31 and [41 represent the massive efforts by Guilleman and Schally in order to successfully characterise TRH. For this work they won the Nobel Prize for Medicine.
   Google Scholar
• BURKE TR, LIM B, MARQUEZ VE, LI Z-H, BOLEN JB, STEFANOVA I, HORAK ID: Bicyclic compounds as ring-constrained inhibitors of protein-tyrosine kinase p561ck. J. Med. Chem. (1993) 36:425–432.
   PubMed Web of Science ®Google Scholar
• BURKE TR: Protein-tyrosine kinase inhibitors. Drugs Fut.(1992) 17:119–131.
   Google Scholar
• BURSTEN SL, HARRIS WE, BIANCO JA, SINGER JW: CT-1501R inhibits rapid synthesis of specific phosphatidic acid (PA) species following stimulation of tumor ne-crosis factor alpha (TNFa) type 1 but not type 11 receptors. Blood (1994) 82: 363A. (Abstr.)
   Google Scholar
• BURSTEN SL, HARRIS WE, BOMSZTYK K, LOVETT D: Interleukin-1 rapidly stimulates lysophosphatidate acyltransferase and phosphatidate phosphohydrolase activities in human mesangial cells. Journal of Biological Chemistry (1991) 266: 20732–20743.
   PubMed Web of Science ®Google Scholar
• BURSTEN SL, HARRIS WE: Interleukin-1 stimulates phos-pholipase D activity in human mesangial cells. AmJ.Physiol. (1994) In press.
   Google Scholar
• BURSTEN SL, RICE GC, CHANEY R, HARRIS WE: Inter-leukin-113 01–13) and tumor necrosis factor a (TNFa) signal through structurally distinct phosphatidic acid (PA) molecules in human umbilical vein endothelial cells (HUVEC). Clin.Res. (1994) Submitted:
   Google Scholar
• BUSE MG, JOHNSON All, KUPERMINC D, BUSE J: Effect ofa-adrenergic blockade on insulin secretion in man. Metabolism (1970) 19:219–225.
   PubMedGoogle Scholar
• CADENA DL, GILL GN: Receptor tyrosine kinases. FASEBJ. (1992) 6:2332–2337.
   PubMed Web of Science ®Google Scholar
• CAMERON RB, MCINTOSH JK, ROSENBERG SA: Synergisticantitumor effects of combination immunotherapy with recombinant interleukin- 2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Res. (1988) 48:5810–5817.
   PubMed Web of Science ®Google Scholar
• CANTLEY LC, AUGER KR, CARPENTER C, DUCKWORTH B,GRAZIANI A, KAPELLER R, SOLTOFF S: Oncogenes and signal transduction. Cell (1991) 64:281–302.
   PubMed Web of Science ®Google Scholar
• CARLAN SJ, O'BRIAN WF, O'LEARY TD, MASTROGIANNISD: Randomized comparative trial of indomethacine and sulindac for treatment of refractory pre-term labour. Obstetrics and Gynecology (1992) 79:223–228.
   PubMed Web of Science ®Google Scholar
• CARLSEN E, GIWERCMAN A, ICEIDING N, SICAKKABAEK NE: Evidence for decreasing quality of semen during the past 50 years. Brit. Med. J. (1992) 305:609–613.
   PubMed Web of Science ®Google Scholar
• This paper has attracted much publicity in the media recently (e.g. BBC Horizon: male infertility, 11th April 1994), and suggests that the observed decrease in sperm count since 1940 may be due to environmental factors.
   Google Scholar
• CARTWRIGHT C, KAMPS M, MEISLER A, PIPAS J, ECKHART W: pp60c- src activation in human colon cancer. J. Clin. Invest. (1989) 83: 2025–2032.
   PubMed Web of Science ®Google Scholar
• CHAN CB, MACPHAIL RM: Functional characterization of a-adrenoceptors on pancreatic islets of fa/fa Zucker rats. Mol. Cell Endocrinol. (1992) 84:33–37.
   PubMed Web of Science ®Google Scholar
• CHAN SLF, BROWN CA, MORGAN NG: Stimulation of Insulin secretion by the hnidazoline a2-adrenoceptor antagonist efaroxan is mediated by a novel, stereose- lective, binding site. Eur.J.Pharmacol. (1993) 230:375–378.
   PubMed Web of Science ®Google Scholar
• Direct evidence for involvement of a non-adrenergic imidazoline receptor in control of insulin secretion.
   Google Scholar
• CHAN SLF, DUNNE MJ, STILIINGS MR MORGAN NG: The a2-adrenoceptor antagonist efaroxan modulates KATp channels in insulin secreting cells. Eur. J. Pharmacol. (1991) 204:41–48.
   PubMed Web of Science ®Google Scholar
• CHAN SLF, MORGAN NG: Characterisation of the a2-ad-renoceptor subtype responsible for inhibition of Insu-lin secretion in isolated rat islets. In: Adrenoceptors-Structure, Mechanisms and Function (1991) Birkhauser-Ver-lag, Basel pp 311–312.
   Google Scholar
• CHAN SLF, MORGAN NG: Expression of mRNA for mul-tiple a2-adrenoceptor subtypes in insulin secreting cells. Diabetologia (1993) 36\(Supp1.1)A81.
   Google Scholar
• CHAN SLF, MORGAN NG: Stimulation of insulin secre-• tion by efaroxan may involve interaction with potas-sium channels. Eur. J. Pharmacol. (1990) 176:97–101.
   PubMed Web of Science ®Google Scholar
• CHAN SLF: Role of a2-adrenoceptors and imidazoline-binding sites in the control of insulin secretion. Clin. Sci. (1993) 85:671–677.
   PubMed Web of Science ®Google Scholar
• Timely review of the involvement of imidazoline binding sites in regulation of islet KATP channels, and insulin secretion with empha-sis on the relationship between these sites and a2-adrenoceptors.
   Google Scholar
• CHANG CJ, GEAHLEN RL: Protein-tyrosine kinase inhibi-tion - mechanism-based discovery of antitumor agents. I Nat. Prod. (1992) 55:1529–1560.
   PubMed Web of Science ®Google Scholar
• CHECK JH, BOLLENDORF A: Improved motility of retro-grade ejaculation by adding donor seminal plasma. Arch. Androl. (1990) 25:41–43.
   PubMed Web of Science ®Google Scholar
• CHEN HX, BOIZIAU J, PARKER F, MAROUN R, TOCQUE B, ROQUES BP, GARBAYJALTREGUIBERRY C: Synthesis and structure-activity studies of a series of Khydroxyben-zyDaminolsalicylates as inhibitors of EGF receptor-as-sociated tyrosine kinase activity. J. Med. Chem. (1993) 36:4094–4098.
   PubMed Web of Science ®Google Scholar
• CHIA° PJ, BISCHOFF FZ, STRONG LC, TAINSKY MA: The current status of oncogenes and cancer: Experimental approaches for analyzing oncogenetic events in human cancer. Cancer and Metast. Rev. (1990) 9:63–80.
   PubMed Web of Science ®Google Scholar
• CHIKKALA NF, LEWIS I, ULCHAKER J, STANLEY J, TUBBS R, FIN10E JH: Interactive effects of alpha-interferon a/d and interleukin-2 on murine lymphokine activated killer activity: Analysis at the effector and presursor level. Cancer Res. (1990) 50:1176–1182.
   PubMed Web of Science ®Google Scholar
• CHOU T, CHANG AE, SHIT S: Generation of therapeutic T lymphocytes from tumor bearing mice by in vitro sensitization. J. Immunol. (1988) 140:2453–2461.
   PubMed Web of Science ®Google Scholar
• CHOUAIB S, BERTOGLIO J, BLAY JY, MARCHIOL-FOURNI-GAULT C, FRADELIZI D: Generation of lymphokine-acti-vated killer cells: Synergy between tumor necrosis factor and interleukin-2. Immunology (1988) 85:6875–6879.
   Google Scholar
• CLARK EA, BRUGGE JS: Redistribution of activated pp60c-src to integrin-dependent cytoskeletal com-plexes in thrombin- stimulated platelets. Mol. Cell. Biol. (1993) 13:1863–1871.
   PubMed Web of Science ®Google Scholar
• CLARK J'W, SMITH JW, STEIS RG, URBA WJ, CRUM W, MTH FR R, MCKNIGHT J, BEMAN JA, STEVENSON HC, CREEKMORE S, STEWART M, CONLON K, SZNOL M, KRE-MERS P, COHEN P, LONGO DL: Interleukin-2 and lym-phokine-activated killer cell therapy: Analysis of a bolus interleukin-2 and a continuous infusion inter-leukin-2 regimen. Cancer Res. (1990) 59:7343–7350.
   Google Scholar
• CLARK SS, CRIST WM, WITITE ON: Molecular pathogenesis of Ph-positive leukemias. Annu. Rev. Med. (1989) 40:113–122.
   PubMed Web of Science ®Google Scholar
• COBB BS, SCHAII.FR MD, LEU TH, PARSONS JT: Stable assodation of pp60(src) and pp59(fyn) with the focal adhesion-associated protein tyrosine kinase, pp125(fak). Mol. Cell. Biol. (1994) 14:147–155.
   PubMed Web of Science ®Google Scholar
• COCKLE SM, AITKEN A, BEG F, MORRELL J, SMYTH DG: The TRH-related peptide pyroglutamylglutamylproli-namide is present in human semen. FEBS Seas. (1989) 252:113–117.
   PubMed Web of Science ®Google Scholar
• First report of FPP in human semen, with full structural charac-terisation of the peptide.
   Google Scholar
• COCKLE SM, AITKEN A, BEG F, SMYTH DG: A novel peptide pyroglutarnyl glutamylprolinamide, in the rab-bit prostate complex, structurally related to thy-rotropin-releasing hormone. J. Biol. Chem. (1989) 264:7788–7791.
   PubMed Web of Science ®Google Scholar
• The first full structural characterisation of FPP, by fast atom bom-bardment (FAB) mass spectrometry.
   Google Scholar
• COLQUHOUN SD ET AL.: 1L-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety oflymphoid tissue. j Surg. Res. (1993) 55:486–492.
   PubMed Web of Science ®Google Scholar
• COORE HG, RANDLE PJ: Regulation of insulin secretion studied with pieces of rabbit pancreas incubated in vitro. Biochem.J. (1964) 93:66–78.
   PubMed Web of Science ®Google Scholar
• COX GW, CHATTOPADHYAY U, OPPENHEIM JJ, VARESIO L: 11-4 inhibits the costimulatory activity of 11-2 or picolinic add but not of lipopolysaccharide on 1FN-gamma treated macrophages. J. Immunol. (1991) 147:3809–3814.
   PubMed Web of Science ®Google Scholar
• COX GW, MATHIESON 13.1, GIARDINA SL, VARESIO L: Characterization of 1L-2 receptor expression and func-tion on murine macrophages. J. Immunol. (1990) 145:1719–1725.
   Google Scholar
• CREAGAN ET, AHMANN DL, GREEN SJ: Phase 11 study of recombinant leukocyte alpha-interferon in dissemi-nated malignant melanoma. Cancer (1984) 54:2844–2849.
   PubMed Web of Science ®Google Scholar
• CREASEY AA, CHANG CK, FEIGEN L, WUN TC, TAYLOR FB HINSHAW LB: Tissue factor pathway inhibitor reduces mortality from Escbericbia colt septic shock. J.Clin.In-vest. (1993) 91: 2850–2860.
   PubMed Web of Science ®Google Scholar
• CUFFMAN RL, OHARA J, BOND MW, CARTY J, ZLOTNICK E, PAUL WE: B cell stimulatory factor-1 enhances the IgE response to liposaccharkle-activated B cells. I Immunol. (1986) 136:4538–4541.
   PubMed Web of Science ®Google Scholar
• DANIAK N, GUIGON M, BROXMEYER HE, LEMOINE F, NAJMAN A: Meeting on negative regulation of he-matopoietic cell growth and differentiation. Exp.Heina-tol. (1994) 22: 399–405.
   Google Scholar
• DANIS VA, FRANIC GM, RATHJEN DA, BROOKS PM: Effects of granulocyte-macrophage colony-stimulating factor (GM-CSF), 11-2, interferon-gamma, tumor necrosis fac-tor-alpha and IL-6 on the production of immunoreac-tive IL-1 and TNF- alpha by human monocytes. Clin. Exp. Immunol (1991) 85:143–450.
   PubMed Web of Science ®Google Scholar
• DAUGHERTY JP, WEINER LM: Augmentation of I1-2 in-duced IL-2 receptor expression by 1FN-gamma. Proc. Amer. Assoc. Cancer Res. (1987) 28:341–344.
   Web of Science ®Google Scholar
• DEFRANCE T, VANBERVLIET B, AUBRY J, BANCHEREAU J: Interleukin-4 inhibits the proliferation but not the differentiation of actvated human B cells in responce to interleuldn-2. J. Exp. Med. (1988) 168:1321–1333.
   PubMed Web of Science ®Google Scholar
• DELLI-BOVI P, BASILIC° C: Isolation of a rearranged human transforming gene following transfection of Kaposi sarcoma DNA. Proc. Natl. Acad. Sci. USA (1987) 84:5660–5664.
   PubMed Web of Science ®Google Scholar
• DI FIORE PP, PIERCE JH, KRAUS ME-I, SEGATTO O, KING CR, AARONSON SA: erbB-2 is a potent oncogene when overexpressed in N1H/3T3 cells. Science (1987) 237:178–182.
   PubMed Web of Science ®Google Scholar
• References 85 and 86 provide the first demonstration that normal c-erbB-2 can transform cells.
   Google Scholar
• DICKSON C, PhILRS G: Potential oncogene product related to growth factors. Nature (1987) 326:833.
   PubMed Web of Science ®Google Scholar
• DIRAIMONDO F, LAPUSHIN R, HERSH EM: Synergism between alpha-interferon and interleukin-2 activated killer cells: in vitro studies. Acta Haematologica (1987) 78:77–83.
   PubMed Web of Science ®Google Scholar
• DITTADI R, GION M, PAGAN V, BRAZZA.LE A, MASCHIO OD, BARGOSSI A, BUSETTO A, BRUSCAGNIN G: Epider-mal growth factor receptor in lung malignancies. Com-parison between cancer and normal tissue. Br.J. Cancer (1991) 64:741–744.
   PubMedGoogle Scholar
• DOHERTY GM, LANGE JR, LANGSTEIN HN, ALEXANDER HR, BURESH CM, NORTON JA: Evidence for 1FN-y as a mediator of the lethality of endotoxin and tumour necrosis factor alpha. J.Immunol. (1992) 149: 1666–1670.
   PubMed Web of Science ®Google Scholar
• DOOLITTLE RE, HUNKAPILLER MW, HOOD LE, DEVARE SG, ROBBINS KC, AARONSON SA, ANTONIADES HN: Sim-ian sarcoma virus onc gene, v-sir, is derived from the gene (or genes) encoding a platelet-derived growth factor. Science (1983) 221:275–277.
   PubMed Web of Science ®Google Scholar
• DOUGALL WC, QIAN X, GREENE MI: Interaction of the neu/p185 and EGF receptor tyrosine kinases: Implica-tions for cellular transformation and tumor therapy. J. Cell. Biolchem. (1993) 53:61–73.
   Google Scholar
• DREBIN JA, LINK VC, GREEN MI: Monoclonal antibodies reactive with distinct domains of the neu oncogene-en-coded p185 molecule exert synergistic antitumor ef-fects. Oncogene (1988) 2:273–277.
   PubMed Web of Science ®Google Scholar
• Demonstration that erbB-2 is a viable target in cancer chemotherapy.
   Google Scholar
• DREBIN JA, LINK VC, GREENE ME: Monoclonal antibodies specific for the nett oncogene product directly mediate antitumor effects in vivo. Oncogene (1988) 2:387–394,
   PubMed Web of Science ®Google Scholar
• DREBIN JA, LINK VC, WEINBERG RA, GREENE MI: Inhibi-tion of tumor growth by a monoclonal antibody reac-tive with an oncogene-encoded tumor antigen. Proc. Natl. Acad. Sci. USA (1986) 83:9129–9133.
   PubMed Web of Science ®Google Scholar
• DUBINETT SM, KURNICK yr, KRADIN RL: Analysis of the local inflammatory response to adoptive immuno-therapy with activated lymphocytes, IFN-gamma, and IL-2. EASES J. (1988) 2:2286.
   Google Scholar
• DUFF P, KOPELMAN JN: Subclinical intra-amniotic infec-tion in asymptomatic patients with refractory preterm labor. Obstet. Gynecol. (1987) 69:756–759.
   PubMed Web of Science ®Google Scholar
• DUNNE MJ: Block of ATP-regulated potassium channels by phentolaminr and other alpha-adrenoceptor an-tagonists. Br. J. Pharmacol. (1991) 103: 1847–1850.
   PubMed Web of Science ®Google Scholar
• DUTCH1R JP, CREEKMORE S, WEISS GR, ATKINS MB: A phase II study of interleukin-2 and LAK cells in patients with metastatic malignant melanoma. J. Clin. Oncol. (1989) 7:477–485.
   PubMed Web of Science ®Google Scholar
• DVIR A, MILNER Y, CHOMSKY O, GLLON C, GAZIT A, LEvrrziu A: The inhibition of EGF-dependent prolifera-tion of keratinocytes by tyrphostin tyrosine kinase blockers. J. Cell Biol. (1991) 113:857–865.
   PubMed Web of Science ®Google Scholar
• EARDLEY DD, KOSHLAND ME: Glycosylphosphatidyli-nositol A candidate system for interleukin-2 signal transduction. Science (1991) 251: 78–81.
   PubMed Web of Science ®Google Scholar
• EASON MG, LIGGETT SB: Human a2-adrenergic receptor subtype distribution: widespread and subtype selective expression of oucio, oucs and a2C2 MRNA in multiple tissues. Mol. Pharmacol. (1993) 44:70–75.
   PubMed Web of Science ®Google Scholar
• EDWARDS BS, HAWIUNS MJ, BORDEN EC: Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity. Cancer Res. (1984) 44:3135–3139.
   PubMed Web of Science ®Google Scholar
• EDWARDS BS, HAWKINS MJ, BORDEN EC: Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-Laterferons differing in antiviral activity. Cancer Res. (1984) 44:3135–3139.
   PubMed Web of Science ®Google Scholar
• ELDER JT, FISHER GJ, LINDQUIST PB, BENNET GL, PIT-TELKOW MR, COFFEY RJ, ELLINGSWORTH L, DENRYNCK R, VOORHEES JJ: Overexpression of transforming growth factor a in psoriatic epidermis. Science (1989) 243:811–814.
   PubMed Web of Science ®Google Scholar
• ELEFANTY AG, HARIHARAN IK, CORY S: Bcr-abl, the hallmark of chronic myeloid leukaemia in man, in- duced multiple haemopoietic neoplasms in mice. EMBO (1990) 9:1069–1078.
   PubMed Web of Science ®Google Scholar
• ELLEDGE RM, MCGUIRE WL, OSBORNE CK: Prognostic factors in breast cancer. Sem. Oncol. (1992) 19:244–253.
   PubMed Web of Science ®Google Scholar
• ERNSBERGER PR, WESTBROOKS KL, CHRISTEN MO, SCHAFER SG: A second generation of centrally acting antihypertensive agents act on putative I1-imidazoline receptors./ Cardiovasc. Pharmacol. (1992) 20(Suppl. S10.
   Google Scholar
• ESCOBEDO J, WILLIAMS LT: A PDGF receptor domain essential for mitogenesis but not for many other re-sponses to PDGF. Nature (1988) 87:85–87.
   Google Scholar
• ESPEVIK T, FIGARI I, RANGES GE, PALLADINO MA: Trans-forming growth factor-131 and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lympholrIne-activatedkiller cell activity. J. Immunol. (1988) 140:2312–2316.
   PubMed Web of Science ®Google Scholar
• EVANS BE, LEIGHTON JL, RITTLE RE, GILBERT KF, LUN-DELL GF, GOULD NP, HOBBS DW, DIPARDO RM, VEBER DF, PETTIBONE DJ: Orally active, nonpeptide oxytocine antagonists. J. Med. Chem. (1992) 35(21):3919–27.
   PubMed Web of Science ®Google Scholar
• FACENDOLA G, LABIANCA R, PIZZOCARO G, PIVA L, PEGORARO C, FAUST1NI M, LOMBARDI F, CLERICI M, SCANCI F, SIGNOROLDI A: Recombinant subcutaneous human interleukin-2 and alpha-2b-interferon in the treatment of advanced renal cell cancer Proc. Amer. Soc. Clin. Oncol.(1993) 13:762.
   Google Scholar
• FALLENSTEIN F, SPATLING L, BEHRENS C, ABDALLAH A: Wehengesteuerte Bolustokolyse. In: Bolustokolyse in Theorie und Praxis Spatling L, Fallenstein F (Eds), Steinkopff Verlag Darmstadt, 1993, p135–139.
   Google Scholar
• First concept of 'intelligent' administration of tocolytics, triggered by uterine contractions.
   Google Scholar
• FANNING P, BULOVAS K, SAINI KS, LIBERTINO JA, JOYCE AD, SUMMERHAYES IC: Elevated expression of pp60c-src In low grade human bladder carcinomas. Cancer Res. (1992) 52:1457–1462.
   PubMed Web of Science ®Google Scholar
• FARACE F, MATHIOT C, BRANDELY M, TURSZ T, DORVAL T, POUILLART P, TRIEBEL F, HERCEND T, FRIDMAN WH: Phase I trial with recombinant interleukin-2: Immune activation by AL-2 alone or following pretreatment with recombinant gamma-Interferon. Clin. Exp. Immunol. (1990) 82:194–199.
   PubMed Web of Science ®Google Scholar
• FARRAR J, BENJAMIN W, HILFIKER M, HOWARD M, FARRAR W, FULLER-FARRAR J: The biochemistry, biology, and role of interleukin-2 in the induction of cytotoxic T-cell and antibody forming B cell responses. Immunol. Rev. (1982) 63:129–166.
   PubMed Web of Science ®Google Scholar
• FAVROT M, CAPDEVILLE R, COMBARET V, ZHOU DC, CLAPISSON G, BANCHEREAU J, FRANKS CR, CHOUAIB S, BLAY JY, PHILIP T: Functional and phenotypic modifi-cations induced by 11-4, as a single agent or in combi-nation with 11-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy. Eur. Cytokine Network (1990) 1:141–147.
   PubMedGoogle Scholar
• FAVROT M, COMBARET V, BLAY JY, CAPDEVILLE R, ZHOU DC, CLAPISSON G, CHOUAD3 S, FRANKS CR, PHILLIP T: INF-alpha enhancement of NK and LAK cell functions induced by high-dose 11-2 in human peripheral blood mononuclear cells from patients pretreated with alpha-IFN + II-2. Eur, Cytokine Network (1990) 1:221–227.
   PubMedGoogle Scholar
• FIGLIN RA, BELLDEGRUN A, MODADVER N, ZEFFREN J, DEKERNION J: Concomittant administration of recom- • binant human interleukin-2 and recombinant inter-feron-alpha 2a: An active outpatient regimen in metas-tatic renal cell carcinoma. J. Clin. Oncol. (1992) 10:414–421.
   PubMed Web of Science ®Google Scholar
• FISHER RI, COLTMAN CA, DOROSHOW JH, PAIETTA EL: metastatic renal cancer treated with interleukin-2 and LAK cells. Ann. Inter. Med. (1988) 108:518–523.
   PubMed Web of Science ®Google Scholar
• FLEMING TP, MATSUI T, AARONSON S: Platelet-derived growth factor (PDGF) receptor activation in cell trans-formation and human malignancy. Exp. Gerantol. (1992) 27:523–32.
   PubMed Web of Science ®Google Scholar
• FLEMING TI', MATSUI T, HEIDARAN MA, MOLLOY CJ, ARTRIP J, AARONSON SA: Demonstration of an activated platelet-derived growth factor autocrine pathway and its role in human tumor cell proliferation in vitro. Oncogene (1992) 7:1355–1359.
   PubMed Web of Science ®Google Scholar
• FLETCHER M, GOLDSTEIN AL: Recent advances in the understanding of the biochemistry and pharmacology of interleukin-2. Lymphokine Res. (1987) 6:45–57.
   PubMedGoogle Scholar
• FOLKMAN T, KAGSBRUN M: Angiogenic factors. Science (1987) 235:442–447.
   PubMed Web of Science ®Google Scholar
• FRASER LR, MONKS NJ: Cyclic nucleotides and mammal-ian sperm capachation.JReprod. Fert. (1990) 42(Suppl.):9–21.
   Google Scholar
• FRASER LR, UMAR G, SAYED S: Na-requiring mecha-nisms modulate capacitation and acrosomal exocytosis in mouse spermatozoa. J. Rep rod. Fert. (1993) 97:539–549.
   PubMedGoogle Scholar
• FRASER LR: Minimum and maximum extracelhdar ca2* requirements during mouse sperm capacitation and fertilization in vitro. J. Rep rod. Fert. (1987) 81:77–89.
   PubMedGoogle Scholar
• FRY DW, KRAKER AJ, CONNORS RC, ELLIOTT WL, NELSON JM, SHOWALTER HDH, LEOPOLD WR: Strategies for the discovery of novel tyrosine kinase inhibitors with an-ticancer activity. Anticancer Drug Design. (1994) In press.
   Google Scholar
• FUKAZAWA H, LI PM, YAMAMOTO C, MURAKAMI Y, MIZUNO S, UEHARA Y: Specific inhibition of cytoplas-mic protein tyrosine kinases by herbimycirt-A in vitro. Biochem. Pharmacol. (1991) 42:1661–1671.
   PubMed Web of Science ®Google Scholar
• FUKAZAWA H, MIZUNO S, UEHARA Y: Effects of herbitay-cin A and various SH-reagents on p60v-src. Biochem. Biophys. Res. Comm. (1990) 173:276–282.
   PubMed Web of Science ®Google Scholar
• GALLAGHER G, WILCOX F, ALL-AZZAWI F: Interleukin-3 and interleukin-4 each strongly inhibit the induction and function of human LAK cells. Clin. Exp. Immunol. (1988) 74:166–170.
   PubMed Web of Science ®Google Scholar
• GARCIA R, PARIKH NU, SAYA H, GALLICK GE: Effect of herbimycin-A on growth and pp60c-src activity in hu-man colon tumor cell lines. Oncogene (1991) 6: 1983-1989.
   Google Scholar
• GARRINO MG, HENQUIN JC: Highly potent and stereose-lective effects of benzoic acid derivative AZ-DF 265 on pancreatic O-cells. Br. J. Pharnzacol. (1998) 93:61–68.
   Google Scholar
• GASPARINI G, GULLICK WJ, BEVILACQUA P, SAINSBURY RC, MELT S, BORACCHI P, TESTOLIN A, LA MALFA G, POZZAF: Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J. Clin. Oncol. (1992) 10:686–695.
   PubMed Web of Science ®Google Scholar
• GAYNOR ER, WEISS GR, MARGOLIN ICA, ARONSON FR, SZNOL M, DEMCHAK P, GRIMA KM: Phase I study of high dose continuous infusion recombinant interleukin-2 and autologous lyniphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma. J. Natl. Cancer Institute (1990) 82:1397–1402.
   PubMed Web of Science ®Google Scholar
• GAZIT A, OSHEROV N, POSNER I, BARSINAI A, GILON C, LEVITZKI A: Tyrphostins. 3. Structure-activity relation-ship studies of alpha-substituted benzylidene-malononitrile 5-5-aryltyrphostins. J. Med. Chem. (1993) 36:3556–3564.
   Google Scholar
• GAZIT A, OSHEROV N, POSNER I, YAISH P, PORADOSU E, GILON C, LEVITZKI A: lyrphostins. 2. Heterocyclic and a-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and erbB2/neu tyro-sine kinases. J. Med. Chem. (1991) 34:1896–1907.
   Google Scholar
• GAZIT A, YAISH P, GILON C, LEVITZKI A: Tyrphostins. 1. Synthesis and biological activity of protein tyrosine kinase inhibitors. J. Med. Chem. (1989) 32:2344–2352.
   Google Scholar
• GEISSLER JF, ROESEL JL, MEYER T, TRINKS UP, TRAXLER P, LYDON NB: Benzopyranones and benzothiopyra-nones: A class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase. Cancer Res. (1992) 52:4492–4498.
   PubMed Web of Science ®Google Scholar
• GEISSLER JF, TRAXLER P, REGENASS U, MURRAY BJ, ROE- SEL JI.„ MEYER T, MCGLYNN E, STORNI A, LYDON NB:Thiazolidine-diones. Biochemical and biological activ-ity of a novel class of tyrosine protine kinase inhibitors. J. Biol. Chem. (1990) 265:22255–22261.
   Google Scholar
• GEROSA F, TOMMASI M, GEROSA M, TRIDENTE G: Human recombinant interleukin-4 inhibits lymphokine-acti-vated killer activity of sheep erythrocyte rosette-form-ing and non-forming human lymphocytes. Intern. J. Cancer (1988) 42:902–905.
   PubMed Web of Science ®Google Scholar
• GMT FSPIE J, DYE JF, SCHACHTER M, GUILLOU PJ: Inhibi-tion of pancreatic cancer cell growth in vitro by the tyrphostin group of tyrosine kinase inhibitors. Brit. J. Cancer (1993) 68:1122–1126.
   PubMed Web of Science ®Google Scholar
• GBUS S, FERM MM, OU W, SMITH KA: T-cell growth-fac-tor: Parameters of production and a quantitative mi-croassay for activity. J. Immunol. (1978) 120:2027–2031.
   PubMed Web of Science ®Google Scholar
• GIMBRONE MAJ, OBIN MS, BROCK AF, LUIS EA, HASS PE, HEBERT CA, YIP YK, LEUNG DW, LOWE DG, KOHR WJ, DARBONNE WC, BECHTOL KB BAKER JB: Endothelial interleukin-8: a novel inhibitor of leukocyte-endothe-lial interactions. Science (1989) 246: 1601-1603.
   Google Scholar
• GISHIZKY ML, JOHNSON-WHITE J, WITTE ON: Efficient transplantation of BCR-ABL-induced chronic myelo-genous leukemia- like syndrome in mice. Proc. Natl. Acad. Sci. USA (1993) 90:3755–3759.
   PubMed Web of Science ®Google Scholar
• GKONOS PJ, KWOK CK, BLOCK NL, ROOS BA: Expression of prostatic TRH-like peptides differs between malig-nant and non-malignant tissues. The Prostate (1993) 23:135–147.
   PubMed Web of Science ®Google Scholar
• GLENNEY JR: Tyrosine-phosphorylated proteins - me-diators of signal transduction from the tyrosine ki-nases. Biochim. Biophys. Acta (1992) 1134:113–127.
   PubMed Web of Science ®Google Scholar
• GOLICHOWSKI AM, HATHAWAY DR, FINEBERG N, PELEG D: Tocolytic and hemodynamie effects of nifedipine In the ewe. Am. J. Obstet. Gynecol. (1985) 151:1134-1140. As [161
   Google Scholar
• GOYERT G, WOLFE H, BHATIA R, NORMAN G, FARAG AM, MAMMEN E: Evaluation of potential early markers of chorioamnionitls associated with preterm premature ruptured membranes. Am. J. Perinatol. (1990) 7:33–35.
   PubMed Web of Science ®Google Scholar
• GRACOMINI P, AGUZZI A, PESTKA S: Modulation by recombinant DNA leukocyte (alpha) and fibroblast(beta) interferons of the expression and shedding of HLA and tumor-associated antigens by human mela-noma cells. J. Immunol. (1984) 133:1649–1655.
   PubMed Web of Science ®Google Scholar
• GRAZIANI A, GRAMAGLIA D, DALLA ZONCA P, COMO- GLIO PM: Hepatocyte growth factor/scatter factor stimulates the ras-guanine nucleotide exchanger. J. Biol. Chem. (1993) 268:9165–9168.
   PubMed Web of Science ®Google Scholar
• GREEN CM, COCKLE SM, WATSON PF, FRASER LR: Stimu-lating effect of pyroglutamylglutamylprolineamide, a prostatic TRH-related tripeptide, on mouse sperm ca-pacitation and fertilizing ability in vitro. Mol. Reprod. Devel. (1994) 38(2): 215–221.
   PubMed Web of Science ®Google Scholar
• The first definitive evidence for an important physiological role for FPP in activation of spermatozoa.
   Google Scholar
• GRIMAUX M, ROMAIN S, REMVIKOS Y, MARTIN PM, MAG-DELENAT H: Prognostic value of epidermal growth factor receptor in node-positive breast cancer. Breast Cancer Res. Treat. (1989) 14:77–90.
   PubMed Web of Science ®Google Scholar
• GRIMM EA, MAZUMDER A, ZHANG HZ, ROSENBERG SA: Lymphokine-activated killer cell phenomenon. J. Exp. Med. (1982) 155:1823–1841.
   PubMed Web of Science ®Google Scholar
• GROSPIETSCH G: ZUSATZ BZW. Begleittherapie. In: Toko-lyse mit BetastimuLatoren, Grospietsch G, Kuhn W (Eds.)Thieme, Stuttgart, New York, 1983, p186–187.
   Google Scholar
• GROSS JL, HERBUN WF, DUSAK BA, CZERNIAK P, DIA-MOND MD, SUN T, EIDSVOOG K, DEXTER DL, YAYON A: Effects of modulation of basic fibroblast growth factor on tumor growth in vivo. JNCI (1993) 85:121–131.
   PubMed Web of Science ®Google Scholar
• GROSSMAN Z, HERBERMAN RB: Natural killer cells and their relationship to T cells: Hypothesis on the role of T cell receptor gene rearrangement on the course of adoptive differentiation. Cancer Res. (1986) 46:2651–2658.
   PubMed Web of Science ®Google Scholar
• GUAN E, ZHOU T, WANG J, HUANG P, TANG W, ZHAO M, CHEN Y, SUN Y: Growth inhibition of human naso-pharyngeal carcinoma in athymic mice by anti-epider-mal growth factor receptor monoclonal antibodies. Internat. J. Cell Clon. (1989) 7:242–256.
   PubMedGoogle Scholar
• GUIDOT DM, RICE GC, SINGER JW, BURSTEN SL, BIANCO JA, REPINE JE: Inhibition of lyso-phosphatidic acid acyl transferase (LPAAT) activity by CT1501R suppresses neutrophil adherence and chemotaxis in vitro and decreases interleukin-8 (IL-8)-induced injury in isolated rat lungs perfused with human neutrophils. Clin.Res. (1994) 42: 145A. (Abstr.).
   Google Scholar
• GUILLOT E, ANGEL I, COSTE A, PROUTEAU M, PIVEUX B, COMTE G, LANGER SZ: Effect of alpha-2 adrenoceptor blockade by SL 86.0715 on glucose tolerance in obese zucker rats. Diabetologia (1993) 36\(Suppl. 1)A87.
   Google Scholar
• GULLICK WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br. Med. Bulletin (1991) 47:87–98.
   PubMed Web of Science ®Google Scholar
• GUSELLA GL, ET AL.: IL-2 up-regulates but LEN-gamma suppresses IL-8 expression inhuman monocytes. J. Im-munol. (1993) 151:2725–2732.
   Google Scholar
• GUY CT, MUTHUSWAMY SK, CARDIFF RD, SORIANO P, MULLER WJ: Activation of the c-src tyrosine kinase is required for the induction of mammary tumors in transgenic mice Genes & Develop. (1994) 8:23–32.
   Google Scholar
• PP60c-src kinase activity is necessary for the development of mam-mary tumors in mice transfected with the polyoma middle T oncogene.
   Google Scholar
• GUY CT, WEBSTER MA, SCHALLER M, PARSONS TJ, CAR-DIFF RD, MULLER WJ: Expression of the neu proto-on-cogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci USA (1992) 89:10578–10582.
   PubMed Web of Science ®Google Scholar
• GUZICK DS, WINN K: The association of preterm labour with preterm delivery. Obstet. Gynecol. (1985) 65:11–15.
   PubMed Web of Science ®Google Scholar
• HAAS HG, MEYER R, STEGEMANN M: Calcium-Magne- sium-Interaktion am Herzmuskel: Reaktionen an der Zelloberfliche. In: Medizin, Managment, Magnesium. Weidinger H (Ed) Blackwell Uebereuter, Berlin, 1990, p184–198.
   Google Scholar
• Very important in vitro study for the understanding of the calcium antagonistic mechanism of magnesium at the cell membrane
   Google Scholar
• HAJJAR DP, POMERANTZ KB: Signal transduction in • atherosclerosis: integration of cytokines and the ei-cosanoid network FASEB J. (1992) 6:2933–2941.
   Google Scholar
• HALABAN R: Growth factors and tyrosine protein Id-nases in normal and maligant melanocytes. Cancer Metast. Rev. (1991) 10:129–140.
   PubMed Web of Science ®Google Scholar
• HALLAHAN DE, SPRIGGS DR, BECKETT MA, KUFE DW, WEICHSELBAUM RR: Increased tumour necrosis factor-a mNRA after cellular exposure to ionizing radiation. Proc .Natl.Acad.Sci.(USA) (1989) 86: 10104–10109.
   PubMed Web of Science ®Google Scholar
• HAMAGUCHI M, XIAO H, UEHARA Y, OHNISHI Y, NAGAI Y: Herbimycin-A inhibits the association of p60(v-src) with the cytoskeletal structure and with phosphatidyll-nosito1-3' kinAse. Oncogene (1993) 8:559–564.
   PubMed Web of Science ®Google Scholar
• HAMBLIN J, DAVIES B, SADULLAH S, OSKAM R, PALMER P, FRANKS CR: A phase II study of the treatment of metas-tatic malignant melanoma with a combination of dacar-bazine, cisplatin, interleukin-2 and alpha-interferon. Europ. J. Cancer (1991) 27:123–127.
   Google Scholar
• HAMEED C, TEJANI N, VERMA UL: Silent chorioamnioni- tis as a cause of preterm labour refractory to tocolytic therapy. Am. J. Obstet. Gynecol. (1984) 149:726–730.
   PubMed Web of Science ®Google Scholar
• HAN ZC, LEBEURIER, I, CAEN, JP: Negative regulation of megakaryocytopoiesis. In: The negative regulation of he-matopoiesis from fundamental aspects to clinical applica-tions. Guidon M, Lemoine FM, Dainiak N, Schechter A, Najm:an A (Eds) John Libbey Eurotext, 1993,
   Google Scholar
• HARANAKA K, SATOMI N, SAKURAI A: Antitumor activity of tumor necrosis factor against transplantable murine tumors and heterotransplanted human tumors in nude mice. Intern. J. Cancer (1984) 34:263–267.
   PubMed Web of Science ®Google Scholar
• HARIHARAN IK, HARRIS AW, CRAWFORD M, ABUD H, WEBB E, CORY S, ADAMS J: bcr-v-abi oncogene induces lymphomas in transgenic mice. Mol. Cell. Biol. (1989) 9:2798–2805.
   PubMed Web of Science ®Google Scholar
• HARRISON RAP, ROLDAN ERS: Phosphoinositides and their products in the mammalian sperm acrosome reaction. J. Reprod. Fert. (1990) 42(Suppl.): 51–67.
   Google Scholar
• HARVEY S, TRUDEAU VL, ASHWORTH RJ, COCKLE SM: pGlutamylglutamyl prolineamide modulation of growth hormone secretion in domestic fowl: antago-nism of thyrotrophin-releasing hormone action? J. En-docrinol. (1993) 138:137–147.
   PubMedGoogle Scholar
• HARWERTH IM, WELS W, SCHLEGEL J, MULLER M, HYNES NE: Monoclonal antibodies directed to the erbb-2 recep-tor inhibit in vivo tumour cell growth. Brit. J. Cancer (1993) 68:1140–1145.
   PubMed Web of Science ®Google Scholar
• HATJIS CG, SWAIN M: Systemic tocolysis for premature labor is associated with an increased incidence of pulmonary edema in the presence of maternal infec-tion. Am. J. Obstet. Gynecol. (1988) 159:723–728.
   PubMed Web of Science ®Google Scholar
• HAUGEN DR, AKSLEN LA, VARHAUG JE, LILLEHAUG JR: Demonstration of a TGF-alpha-EGF-receptor autocrine loop and c-myc protein over-expression in papillary thyroid carcinomas. Int.J. Cancer (1993) 55:37–43.
   PubMed Web of Science ®Google Scholar
• HAYAKAWA K, FUKUSHIMA T, SEITO D, ASAICURA Y, YAMANAKA Y, MORITA T, SASAKI M, KONN M, ONO K: Continuous arterial infusion therapy of recombinant interleukin-2 and cylophosphamide in liver metastasis. Gan to Kagaku Ryobo (1989) 16:2842–2844.
   PubMedGoogle Scholar
• HAYMAN MJ, ENRIETTO PJ: Cell transformation by the epidermal growth factor receptor and v-erbB. Cancer Cells (1991) 3:302–307.
   PubMed Web of Science ®Google Scholar
• HEISTERKAMP N, JENSTER G, TEN HOEVE J, ZOVICH D, PATTENGALE PK, GROFFEN J: Acute leukaemia inbcr/abl transgenic mice. Nature (1990) 344:251–253.
   PubMed Web of Science ®Google Scholar
• HENDLER FJ, SHUM-SIU A, OECHSLI M, NANUL, RICHARDS CS, OZANNE BW: Increased EGF-R1 binding predicts a poor survival in squamous tumors. Cancer Cells (1989) 7:347–351.
   Google Scholar
• HENNEY CS, KURIBAYASHI K, KERN DF, GILLIS S: Inter-leukin-2 augments natural killer cell activity. Nature (1981) 291:335–338.
   PubMed Web of Science ®Google Scholar
• HENNIPMAN A, VAN OIRSCHOT BA, SMITS J, RIJKSEN G, STAAL GEJ: Tyrosine ldnase activity in breast cancer, benign breast disease, and normal breast tissue. Cancer Res. (1989) 49:516–521.
   PubMed Web of Science ®Google Scholar
• HENQUIN JC, GARRINO MG, NENQUIN M: Stimulation of Insulin release by benzoic acid derivatives related to the non-sulphonylurea moiety of glibendamide: structural requirements and cellular mechanisms. Eur.J. Pharma-col. (1987) 141:243–251.
   PubMed Web of Science ®Google Scholar
• HENRY JA, HENNESSY C, LEVETT DL, LENNARD 1 WJ, WESTLEY BR, MAY FEB: Int-2 amplification in breast cancer: association with decreased survival and rela-tionship to amplification of c-erbB-2 and c-myc. Int. J. Cancer (1993) 53: 774–780.
   PubMed Web of Science ®Google Scholar
• HERBERMANN RB, ORTALDO JR, MANTOVANI A, HOBBS DS, KUNG HF, PESTKA S: Effect of human recombinant Interferon on cytotoxic activity of natural killer cells and monocytes. Cell Immunol. (1982) 67:160–167.
   PubMed Web of Science ®Google Scholar
• HERRMANN F, GEBAUER G, LINDEMANN A, BRACH M, MERTELSMANN RH: Interleukin-2 and interferon-gamma recruit different subsets of human peripheral blood monocytes to secrete interleuldn-1 and tumor necrosis factor-alpha. din. Exp. Immunol. (1989) 77:97.
   PubMed Web of Science ®Google Scholar
• HERSH EM, MURRAY JL, HONG WK, ROSENBLUM MG, REUBEN JM, WEILBAECHER R, SARWAL AN, BRADLEY EC, KONRAD M, ARNETT FC: Phase I study of cancer therapy with recombinant interleukin-2 administered by intra-venous bolus injection. Biotherapy (1989) 1:215–226.
   PubMedGoogle Scholar
• HESLOP HE, GOTTLIEB DJ, BIANCHI ACM, MEAGER EA, PRENTICE HG, MEHTA AB, HOFFBRAND AV, BRENNER AK: In vivo induction of gamma interferon and tumor necrosis factor hyinterleukin-2 infusion following in- tensive chemotherapy or autologous marrow bone transplantation. Blood (1989) 74:1374–1380.
   PubMed Web of Science ®Google Scholar
• HIDDEMANN W, RUELFS C, OrlF.NSMEIER C, RUCKLE H, MUSCH E, KOCH O, VAN DE LOO J: Interleukin-2 fol-lowed by 5-fluorouracil and folinic add in refractory colorectal cancer- results of a phase II study. Semin. Oncol. (1992) 19:225–227.
   Google Scholar
• HIEBLE JP, SULPIZIO AC, GOLDSTEIN RS: Determination of the a-adrenoceptor subtype involved in modulation of the response to glucose challenge in the rat. Pbarma-col. Commun. (1992) 1:59–69.
   Google Scholar
• Provides evidence for the involvement of an atypical ce2-adrenocep-tor in regulation of insulin secretion.
   Google Scholar
• HIGUCHI CM, THOMPSON JA, LINDGREN CG, GILLIS S, WIDMER MB, KERN DE, FEFER A: Induction of lymphok-ine-activated killer activity by interleukin-4 in human lymphocytes preactivated by interleulcin 2 in vivo or in vitro. Cancer Res. (1989) 49:6487–6492.
   PubMed Web of Science ®Google Scholar
• HILSTEAD J, RICHTER E, MADSBAD S, -MONIER B, CHRIS-TENSEN NJ, HILDEBRANDT P, DAMJICER M, GALBO H: Metabolic and cardiovascular responses to epinephrine In diabetic autonomic neuropathy. N. Eng. J. Med. (1987) 317:421–426.
   PubMed Web of Science ®Google Scholar
• HILTMANN W D, WISCHNIK A: Magnesium und foetaler Bhnflu13. In: Medizin, Management, Magnesium. Weidinger H (Ed) Blackwell Ueberreuther, Berlin, 1990 n321-324, First study about the acute foetal haemodynamic effect of bolus administration of magnesium sulphate as physiologic calcium an-tagonist
   Google Scholar
• HIRSH M, LIPTON A, HARVEY H, GIVANT E, HOPPER K, JONES G, ZEFFREN J, LEVITT D: Phase I study of inter-leukin-2 and interferon alpha-2a as outpatient therapy for patients with advanced malignancy. J Clin. Oncol. (1990) 8:1657–1663.
   PubMed Web of Science ®Google Scholar
• HOKFELT T, TSURUO Y, ULFHAKE B, CULLHEIM S, ARVIDSSON U, FOSTER GA, SCHULZBERG M, SCHALL1NG M, ARBORELIUS L, FREEDMAN J, POST C, VISSER T: Distri-bution of TRH-like itnmunoreactivity with spedal ref-erence to co-existence with other neuroactive compounds. Ann. NY Acad. Sci. (1989) 553:76–105.
   PubMed Web of Science ®Google Scholar
• HOLLOWAY BR, HOWE R, RAO BS, STRIBLING D: ICI 198157: a novel selective agonist of brown fat and thermogenesis. In: Obesity in Europe Libbey, London (1988) pp 323–328.
   Google Scholar
• HOLMES WE, SLIWKOWSKI MX, AKITA RW, HENZEL WJ, LEE J, PARK JW, YANSURA D, ABADI N, RAAB H, LEWIS GD, SHEPARD HM, KUANG WJ, WOOD WI, GOEDDEL DV, VANDLEN RL: Identification of heregulin, a spedfic activator of p185(erbb2). Science (1992) 256: 1205–1210.
   PubMed Web of Science ®Google Scholar
• HOMA ST, KHAN SN, CONROY DM, SPEAK AE, SMITH AD: Verapamil inhibits phosphatidic acid formation and modifies phosphoinositide metabolism in stimulated platelets. EuropJ.Pharmacol. (1990) 182: 457–464.
   PubMed Web of Science ®Google Scholar
• HONMA Y, KASUKABE T, HOZUMI M, MASEKI N, SAKURAI M, SAKASHITA A, TSURUOKA N: Induction of differentia-tion of human leukemia cells with a structurally altered c-abl (bcr/abl) gene by herbinrydn A, an inhibitor of tyrosine kinase activity. Leukemia (1992) 6:229–231.
   PubMed Web of Science ®Google Scholar
• HONMA Y, KASUICABE T, HOZUMI M, SHIBATA K, OMURA S: Effects of herbincycin-A derivatives on growth and differentiation of K562 human leukemic cells. Anti-cancer Res. (1992) 12:189–192.
   PubMed Web of Science ®Google Scholar
• HONMA Y, OKABE-ICADO J, HOZUMI M, UEHARA Y, MIZUNO S: Induction of erythroid differentiation of K562 human leukemic cells by herbhnycin A, an inhibi-tor of tyrosine kinase activity. Cancer Res. (1989) 49:331–334.
   PubMed Web of Science ®Google Scholar
• HONMA Y, OKABE-KADO J, KASUKABE T, HOZUMI M, KODAMA H, KAJIGAYA S, SUDA T, MIURA: Herbimycin A, an inhibitor of tyrosine kinase, prolongs survival of mice inoculated with myeloid leukemia Cl cells with high expression of v-abl tyrosine kinase. Cancer Res. (1992) 52:4017–4020.
   PubMed Web of Science ®Google Scholar
• Demonstration of in vivo antitumour activity.
   Google Scholar
• HORI A, SASADA R, MATSUTANI E, NAITO K, SAKUR Y, FUJITA T, KOZAI Y: Suppression of solid tumor growth by hrununoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res. (1991) 51:6180–6184.
   PubMed Web of Science ®Google Scholar
• HSU CYJ, PERSONS P, SPADA AP, BEDNAR RA, LEVITSKI A, ZILBERSTEIN A: Kinetic analysis of the inhibition of the epidermal growth factor receptor tyrosine kinase by lavendustin-A and its analogues. J. Biol. Chem. (1991) 266:21105–21112.
   PubMed Web of Science ®Google Scholar
• HUBERMAN M, BERING H, FALLON B, TESSITORE J, SON-NENBORN H, PAUL S, ZEFFREN J, LEVITT D, GROOPMAN J: A phase! study of an outpatient regimen of recombi-nant human interleukin-2 and alpha-interferon in pa-tients with solid tumors. Cancer (1991) 68: 1708-1713.
   Google Scholar
• HUDZIAK RM, SCHIESSINGER J, ULLRICH A: Increased expression of the putative growth factor receptor p183HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. USA (1987) 84:7159–7163.
   PubMed Web of Science ®Google Scholar
• HUGHES SE, HALL PA: The fibroblast growth factor and receptor multigene families. J. PathoL (1993) 170:219–221.
   PubMed Web of Science ®Google Scholar
• HUMPHREY PA, WONG AJ, VOGELSTEIN B, FRIEDMAN HS, WERNER MH, BIGNER DD BIGNER SH: Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res. (1988) 48:2231–2238.
   PubMed Web of Science ®Google Scholar
• HUNTER T: A tail of two src's: mutatis mutandis. Cell (1987) 49:1–4.
   PubMed Web of Science ®Google Scholar
• HUNTER T: Cooperation between oncogenes. Cell (1991) 64:249–270.
   PubMed Web of Science ®Google Scholar
• IIGO M, SA1CURAI M, SHIMIZU M, IIZUKA T, SAIJO N, HOSHI A: Synergistic inhibition of the growth of adeno-carcinoma 755 by the combination of interleukin-2 and interferon-13. Proc. Japanese Acad. Soc. (1986) 62:275–278.
   Google Scholar
• IIGO M, SAKURAI M, TAMURA T, NAGAHIRO S, HOSHI A: In vivo antitumor activity of multiple infections of recombinant interleukin-2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. Cancer Res. (1988) 48:260–264.
   PubMed Web of Science ®Google Scholar
• INTERSAN (Institute for clinical and pharmaceutical investi-gations) (Ed): Prostacyclin-Synthese-Stimulation in der Hochdrucktherapie (1989) Mainzer Verlagsanstalt.
   Google Scholar
• IOCCA DR, FUJIMURA FK, TANDON AK, CLARK GM, MARK C, LEECHEN GJ, POUNDS GW, 'VENDELY P, OWENS MA, PANDIAN MR, MCGUIRE WL: Correlation of her-2/neu amplification with expression and with other prognos-tic factors in 1103 breast cancers. JNCI (1992) 84:1279–1282.
   PubMed Web of Science ®Google Scholar
• ISAACS A, LINDENMANN J: Virus interference. 1. The interferons. Proc. Royal Soc. Biol. Sciences 147:258.
   Google Scholar
• ISRAEL L, BOAZIZ C, MOLIARD M, MORERE JF, BREAU JL: Phase II study of interieukin-2 in 18 patients with advanced gastrointestinal tract cancers. Proc. ASCO (1991) 10:147.
   Google Scholar
• ITOH K, SHIIBA K, SHIMIZU Y, SUZUIU R, KUMAGAI K: Generation of activated killer cells by recombinant interleukin-2 in colaboration with gamma-interferon. J. Immunol. (1985) 134:3124–3129.
   PubMed Web of Science ®Google Scholar
• JACOBS C, RUBSAMEN H: Expression of pp60c-src pro-tein kinase in adult and fetal human tissue: high activi-ties in some sarcomas and mammary carcinomas. Cancer Res. (1983) 43:1696–1702.
   PubMed Web of Science ®Google Scholar
• JAYE M, LYALL RM, MUDD R, SCHLESSINGERI, SARVER NI; Expression of acidic fibroblast growth factor cDNA confers growth advantage and tumorigenesis to Swiss 3T3 cells. EMBO J. (1988) 7:963–969.
   PubMed Web of Science ®Google Scholar
• JAYE M, SCHLESSINGER J, DIONNE CA: Fibroblast growth factor receptor tyrosine kinases - molecular analysis and signal transduction. Biochim. Biophys. Ada (1992) 1135:185–199.
   PubMed Web of Science ®Google Scholar
• JELINEK DF, LIPSKY PE: Inhibitory influence of IL-4 on human B cell responsiveness. J. Immunol. (1988) 141:164–173.
   PubMed Web of Science ®Google Scholar
• JHAPPAN C, STAHLE C, HARKINS RN, FAUSTO N, SMITH GH, MERLIN() GT: TGF alpha overexpression in trans-genic mice induces liver neoplasia and abnormal devel-opment of the mammary gland and pancreas. Cell(1990) 61:1137–1146.
   PubMed Web of Science ®Google Scholar
• JOHNSON A, BETSHOLTZ C, HELDIN C, WESTERMARK B: Antibodies against platelet-derived growth factor in-hibit acute transformation by simian sarcoma virus. Nature (1985) 317:438–440.
   PubMed Web of Science ®Google Scholar
• JONAS JC, PLANT TD, ANGEL I, LANGER SZ, HENQUIN JC: ht vitro stimulation of insulin release by SL 84.0418, a new a2-adrenoceptor antagonist. Eur. j Pharmacol. (1994) 25427–33.
   Google Scholar
• JONAS JC, PLANT TD, HENQUIN JC: Imidazoline antago-nists of a2-adrenoceptors increase insulin release in vitro by inhibiting ATP-sensitive IC-channels in pan-creatic (3-cells. Br. J. Pharmacol. (1992) 107:8–14.
   PubMed Web of Science ®Google Scholar
• JOVE R, HANAFUSA H: Cell transformation by the viral arc oncogene. Ann. Rev. Biol. (1987) 3:31–56.
   PubMedGoogle Scholar
• KAM JC, ET AL.: Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell re-sponse to glucocorticoids. J. Immunol. (1993) 151:3460–3466.
   Google Scholar
• KAMEDA K, ONO S, KOYAMA I, ABIKO Y: Insulin releas-ing action of 242-(4,5-dihydro-1H-imidazol-2-y1)-1-phenylethyll pyridine dihydrochloride sesquihydrate (DG-5128), a new orally effective hypoglycaemic agent. Acta Endocrinol. (1982) 99:410–415.
   PubMedGoogle Scholar
• KANAMORI A, ABE Y, YAJIMA Y, MANABE Y, ITO K: Epidermal growth factor receptors in plamsa mem-branes of normal and diseased human thyroid glands. J. Clin. Endocrinol. Metab. (1989) 68:899–903.
   PubMed Web of Science ®Google Scholar
• KANZ L, BRUGGER W, BROSS K, MERTELSMANN R: Com-bination of cytokines: Current status and future pros-pects. Br. J. Hematol. (1991) 79:96–104.
   PubMed Web of Science ®Google Scholar
• KAPLAN DR, PERKINS A, MORRISON DK: Signal transduc-tion by receptor tyrosine kinases. In: Oncogenes and Tumor Suppressor Genes in Human Malignancies. Benz CC, Liu ET (Eds), Kluwer Academic Publishers, Boston 1993 pp. 265–279.
   Google Scholar
• KARRAY S, DEFRANCE T, MERLE-BERAL H, BANCHEREAU J, DEBRE P, GALANAUD P: Interleukin-4 counteracts the interleukin-2 induced proliferation of monoclonal B cells. J Exp. Med. (1988) 168:85–97.
   PubMed Web of Science ®Google Scholar
• KASPRZYK PG, SONG SU, DI FIORE PP, KING CR: Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res. (1992) 52:2771–2776.
   PubMed Web of Science ®Google Scholar
• KATAGIRI K, KATAGIRI T, KAJIYAMA K, UEHARA Y, YAMAMOTO T, YOSHIDA T: Modulation of monocytic differentiation of 111-60 cells by inhibitors of protein tyrosine kinases Cellular Immunol. (1992) 140:282–294.
   Google Scholar
• KAUFMANN J, DAVIDSOHN J, LEVANON M, ICEKSON I, REVEL M, RAMOT B: Lymphokine-activated killer cells: Interferon-gamma synergizes with interleukin-2 to in-duce LAK cytotoxicity in homogeneous leukemic preparations. Clin. Immunol. Immunopathol. (1991) 58:278–288.
   PubMedGoogle Scholar
• ICAWAKAMI Y, CUSTER MC, ROSENBERG SA, LOTZE MT: IL-4 regulates IL-2 induction of tymphokine-activated killer activity from human lymphocytes. J. Immunol. (1989) 142:452–3461.
   PubMedGoogle Scholar
• KAWAKAMI Y, ROSENBERG SA, LOTZE MT: Interleukin-4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J. Exp. Med. (1988) 168:2183–2191.
   PubMed Web of Science ®Google Scholar
• 1CAWAZU S, SUZUKI M, NEGISHI K, ISHII J, SANDO H, KATAGIRI H, KANAZAWA Y, YAMANOUCHI S, AKANUMA Y, KAJINUMA H, SUZUKI K, WATANABE, ITOH T, KO-BAYASHI T, KOSAKA K: Initial phase II clinical studies In midaglizole (DG-5128). Diabetes (1987) 36:221–226.
   Google Scholar
• Report of the first clinical trials performed with the hypoglycaemic a2-antagonist midaglizole.
   Google Scholar
• KAWAZU S, SUZUKI M, NEGISHI K, WATANABE T,J:Studies of midagliaole (DG-5128) a new type of oral hypoglycaemic drug in healthy subjects. Diabetes (1987) 36:216–220.
   PubMed Web of Science ®Google Scholar
• ICEATING MT, WILLIAMS LT: Autocrine stimulation of intracellular PDGF receptors in v-sis-transformed cells. • Science (1988) 239:914–916.
   PubMed Web of Science ®Google Scholar
• KEILHOLZ U, SCHEIBENBOGEN C, TILGEN W, BERGMANN L, BRADO B, RICHTER M, SEITHER E, HUNSTEIN W: Treat-ment of metastatic melanoma with interferon-alpha and interleukin-2: Significant improvement with a new dosing schedule. Onkologie (1991) 14:82.
   Google Scholar
• 'CURSE M, GRANT A, KING J: Preterm labour. In: Effective Care in Pregnancy and Childbirth Chalmers I, Enkin M, Keirse M (Eds), Oxford University Press, Oxford, 1989, p694–745.
   Google Scholar
• Evaluation of all randomised and controlled studies concerning management of pregnancy and childbirth
   Google Scholar
• ICELLER JR, SING GK, ELLINGSWORTH LR RUSCEllE FW: Transforming growth factor B: Possible roles in the regulation of normal and leukemic hematopoietic cell growth. J. Cell Biochern. (1989) 39: 175.
   PubMed Web of Science ®Google Scholar
• KELLIE S, HORVATH AR, ELMORE MA: Cytoskeletal targets for oncogetulc tyrosine kinases. J. Cell Sci. (1991) 99:207–211.
   PubMed Web of Science ®Google Scholar
• KELLIHER M, KNOTT A, MCLAUGHLIN J, WITTE ON, ROSENBERG N: Differences in oncogenic potency but not target cell specificity distinguish the two forms of the her /abi oncogene. Ma Cell. Biol. (1991) 11:4710–4716.
   Web of Science ®Google Scholar
• KERN JA, SCHWARTZ DA, NORDBERG JE, WEINER DB, GREENE MI, TORNEY L, ROBINSON RA: p185neu expres-sion in human lung adenocarcinomas predicts short-ened survival. Cancer Res. (1990) 50:5184–5191.
   PubMed Web of Science ®Google Scholar
• KERN JA, TORNEYL, WEINER D, GAZDAR A, SHEPARD HM, FENDLY B: Inhibition of human lung cancer cell line growth by an anti- p185(ber2) antibody. Amer. J. Resp. Cell Mol. Biol. (1993) 9:448–454.
   PubMed Web of Science ®Google Scholar
• KHAYAT D, BOREL C, TOURANI JM, BENHAMMOUDA A, ANTOINE E, VUILLEMIN E, BAZEX PA, 'MILL L, FRANKS R, AUCLERC G, SOUBRANE C, BANZET P, WEIL M: Sequential chemoimmunotherapy with cisplatln, interleukin-2, and interferon alfa-2a for metastatic melanoma. J. Clin. Onc.(1993) 11:2173–2180,
   PubMed Web of Science ®Google Scholar
• KHAZAIE K, SCHIRRMACHER V, LIGHTNER RB: EGF recep-tor in neoplasia and metastasis. CancerMetast. Rev. (1993) 12:255–274.
   PubMed Web of Science ®Google Scholar
• KIM B, FRANCESCHI D, HELMAN S, CLEVELAND RP, IM-BEMBO AL: Interferon inhibition of IL-2 mediated lym-phocyte proliferation. Surgery (1988) 104:390–397.
   PubMed Web of Science ®Google Scholar
• KIM B, STEIN S, WARNAKA P, FRANCESCHI D: Enhanced in vivo therapy of pulmonary metastases with inter-feron and huerleukin. I Surg. Res. (1988) 45:66–73.
   PubMed Web of Science ®Google Scholar
• KIM B, STEIN S, WARNAKA P, FRANCESCHI D: Enhanced in vivo therapy of pulmonary metastases with inter-feron and interleukin. j Swg. Res. (1988) 45:66–73.
   Web of Science ®Google Scholar
• KIM B, WARNAKA P: Enhanced survival of alpha-inter-feron augmented interleukin-2 therapy of pulmonary metastases: Efficiacy comparable to interleukin-2 and lymphokine activated killer cells. J. Sing. Res. (1991) 50:40–46.
   Google Scholar
• KIRCHNER H, LOPEZ-HANNINEN E, FENNER M, VOLKENANDT M, ATZPODIEN J: Chemoimmunotherapy of advanced malignant melanoma with carboplatin and DTIC followed by subcutaneous interleukin-2 and inter-feron-alpha. Proc. Amer. Soc. Clin. Oncol. (1993) 13:1356.
   Google Scholar
• KISS Z: Differential effects of PDGF, serum, and bombe-sin on phospholipase D-mediated hydrolysis of phos-phatidylethanolamine in NIH-3T3 fibroblasts. BiochemJ. (1992) 285: 229–233.
   PubMed Web of Science ®Google Scholar
• KLAGSBRUN M, EDELMAN ER: Biological and biochemi-cal properties of fibroblast growth factors. Implications for the pathogenesis of atherosclerosis. Arteriosclerosis (1989) 9:269–278.
   Google Scholar
• KLEINERMANN ES, KURZROCK R, WYATT D, QUESADA JR, GUTTERMAN JU, FIDLER IJ: Action or suppression of the tumoricidal properties of monocytes from cancer pa-tients following treatment with human recombinant gamma-interferon. Cancer Res. (1986) 46:54001–5404.
   Google Scholar
• KNAUSS TC, JAFFER FE, ABBOUD HE: Phosphatidic acid modulates DNA synthesis, phospholipase C, and plate-let-derived growth factor mRNAs in cultured mesangial cells. Role of protein kinase C. J.Biol.Chem. (1990) 265: 14457–14463.
   PubMed Web of Science ®Google Scholar
• KNOP J, TABORSKI B, DEMAEYER-GUIGNARD J: Selective Inhibition of the generation of T suppressor cells of contact sensitivity in vitro by interferon. J. Immunol. (1987) 138:3684–3687.
   PubMed Web of Science ®Google Scholar
• KOEFFLER HP, RANYARD J, YELTON L: Gamma-inter-feron hiduces expression of ILIA-D antigen on normal and leukemic human myeloid cells. Proc. Nat. Acad. Science USA (1984) 81:4080–4084.
   PubMed Web of Science ®Google Scholar
• KONDO K, WATANABE T, SASAKI H, UEHARA Y, OISHI M: Induction of in vitro differentiation of mouse em-bryonal carcinoma (F9) and etythroleukemia (MEL) cells by herbimycin A, an inhibitor of protein phospho-rylation. J. Cell Biol. (1989) 109:285–293.
   PubMed Web of Science ®Google Scholar
• KOPROWSKI H, HERLYN M, BALABAN G, PARMITER A, ROSS A, NOWELL P: Expression of the receptor for epidermal growth factor correlates with increased dos-age of chromosome 7 in malignat melanoma. Somatic Cell. Ma Genet. Cancer Res. (1985) 11:297–305.
   PubMedGoogle Scholar
• KORNBLUTH J, HOOVER RG: Changes in gene expres-sion associated with IFN-0 and IL-2 induced augmenta-tion of human natural killer cell function. J. Immunol. (1988) 141:3234–3240.
   PubMed Web of Science ®Google Scholar
• 'MAKER AJ, JONES JA, SCHEMMEL ME, MOORE CW: Inhi-bition of epidermal growth factor receptor tyrosine kinase by 2- thioindoles, a new structural class of tyrosine kinase inhibitor. Proc. Am. Assoc. Cancer Res. (1993) 34:408.
   Google Scholar
• KRIGEL RL, PADAVIC-SHALLER KA, RUDOLPH AR, KON-RAD M, BRADLEY EC, GOMIS RL: Renal cell carcinoma: Treatment with recombinant interleukin-2 plus f3-inter-feron. J. Clin. Oncol. (1990) 8:460–467.
   PubMed Web of Science ®Google Scholar
• KRIGEL RL, PADAVIC-SH_ALLER KA, RUDOLPH AR, LI I WIN S, KONRAD M, BRADLEY EC, COMIS RL: A phase I study of recombinant interleukin- 2 plus recombinant O-in-terferon. Cancer Res. (1988) 48:3875–3881.
   PubMed Web of Science ®Google Scholar
• KROWN SE: Interferon treatment of renal cell carci- noma: Current status and future prospectives. Cancer (1987) 59:647–651.
   PubMed Web of Science ®Google Scholar
• KRUIT WHJ, GOEY SH, MONSON JRT, STAHEL RA, CALABRESI F, MERTELSMANN R, HOLDNEREE, EGGER-MONT AMM, BOLDHIUS RLH, DEMULDER PHM, STOTER G: Clinical experience with the combined use of recom-binant interleukin-2 and interferon alpha 2a in metas-tatic melanoma. Br. J. Haematol. (1991) 79:84–86.
   Google Scholar
• KULLANDER S, SVANBERG L: On resorption and the effects of vaginally administered terbutaline in women with premature labor. Acta Obstet Gynecol. Scand. (1985) 64:613–616.
   PubMed Web of Science ®Google Scholar
• One of the few studies dealing with the possibility of local (vaginal) adminsitration of a tocolytic.
   Google Scholar
• KURACHI H, MORISHIGE K-I, AMEMIYA K, ADACHI H, HIROTA K, MIYAKE A, TANIZAWA O: Importance of transforming growth factor alpha/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer cell line in vivo. Cancer Res. (1991) 51: 5956–5959.
   PubMed Web of Science ®Google Scholar
• KURIBAYASHI K, GILLIS S, KERN DE, HENNEY CS: Murine NK cell cultures: Effects of interleukin-2 and interferon on cell growth .1 Immunol. (1981) 126:2321–2327.
   PubMed Web of Science ®Google Scholar
• KURIBAYASHI K, GILLIS S, KERN DE, HENNEY CS: Murine NK cell cultures: Effects of interleukin-2 and interferon on cell growth and cytotoxic reactivity. J. Immunol. (1981) 126:2321–2327.
   PubMed Web of Science ®Google Scholar
• KURZ T, WOLF RA, COKE PB: Phosphatidic acid stimu-lates inositol 1,4, 5-trisphosphate production in adult cardiac myocytes. Circulation Res. (1993) 72: 701–706.
   PubMed Web of Science ®Google Scholar
• LACEY RJ, BERROW NS, LONDON NJM, LAKE SP, JAMES RF, SCARPELLO JHB, MORGAN NG: Differential effects of I3-adrenergic agonists on insulin secretion from pancre-atic islets isolated from rat and man. J Mol. Endocrinol. (1990) 5:49–54.
   PubMed Web of Science ®Google Scholar
• LACEY RJ, CABLE HC, JAMES RFL, LONDON NJM, SCAR-PELLO JHB, MORGAN NG: Concentration-dependent ef-fects of adrenaline on the profile of insulin secretion from isolated human islets of Langerhans. j Endocrinol (1993) 138:555–563.
   PubMed Web of Science ®Google Scholar
• LAROCHELLE WJ, FLEMING TP, AARONSON SA: PDGF in cell transformation. In: Biology of Platelet - Derived Growth Factor. Cytokines. Westermark B, Sorg C (Eds) Basel, Karger 1993, 5:129–145.
   Google Scholar
• Review on the involvement of PDGF in cancer.
   Google Scholar
• LAUZON W, LEMAIRE I : Effect of biological response modifiers on lung natural killer activity. Immunophar-macol. Immunotoxicol. (1991.) 13:237–250.
   PubMed Web of Science ®Google Scholar
• LAUZON W, LEMAIRE I: Effect of biological response modifiers on lung natural killer activity. Immunophar-macol. Immunotoxicol. (1991) 13:237–250.
   PubMed Web of Science ®Google Scholar
• LAUZON W, LEMAIRE I: Effects of biological response modifiers of lung natural killer activity. Immunophar-macol. Immunotaxicol. (1991) 13:237–250.
   PubMed Web of Science ®Google Scholar
• LEE DC, LUEI rEKE NC, PETCH LA: Transforming growth factor-alpha and its role in neoplastic progression. In: Oncogenes and Tumor Suppressor Genes in Human Malig-nancies. Benz CC, Liu ET (Eds), Kluwer Academic Publishers, Boston 1993 pp. 233–254.
   Google Scholar
• LEE DC, LUETTEKE NC, QIU TH, CHEN XR, BERKOWITZ EA: Transforming growth factor-alpha - its expression, #1 regulation, and role in transformation. In: Growth Fac-tors in Perinatal Development. Tsang RC, Lemons JA, Balis-tred (Eds), Raven Press, New York 1993 pp.21–38.
   Google Scholar
• References 31 and 32 provide the latest data on TGF-ct transgenic mice.
   Google Scholar
• LEE EY, WANG TC, CLOUSE RE, DESCHRYVERICECSKEMETI K: Gastric carcinoma, epidermal growth factor, and epidermal growth factor receptor. Gastroenterology (1991) 100:289.
   PubMed Web of Science ®Google Scholar
• LEE KH, TALPAZ M, ROTHBERG JM, MURRAY JL, PA-PADOPOULOS N, PLAGER C, BENJAMIN R, LEVITT D, GUTTERMANN J: Concomittant administration of re-combinant human interleukin-2 and recombinant in-terferon alpha-2a in cancer patients: A phase I study. J Clin. Oncol. (1989.) 7:1726–1732.
   PubMed Web of Science ®Google Scholar
• LEE SH, CHIU H, RINDERKNECHT E, SABO W, STEBBING N: Importance of treatment regimen of interferon as an antitumor agent. Cancer Res. (1983) 43:4172–4175.
   PubMed Web of Science ®Google Scholar
• LEGHA SS, RING S, PLAGER C, PAPADOPOULOS N, GUT-. TERMAN J, BENJAMIN RS: Biochemotherapy using inter-leukin-2 + interferon-alpha 2a in combination with cisplatin, vinblastine, and DITC in advanced melanoma Proc. Amer. Soc. Clin. Oncol. (1991) 10:193.
   Google Scholar
• LEGHA SS: Interferons in the treatment of malignant melanoma. A review of recent trials. Cancer (1986) 57:1675–167.
   Google Scholar
• LEITZEL K, BRYCE W, TOMITA J, MANDERINO G, TRIBBY I, THOMASON A, BILLINGSLEY M, PODCZASKI E, HARVEY H, BARTHOLOMEW M, LIPTON A: Elevated plasma plate-let-derived growth-factor-b-chain levels in cancer pa-tients. Cancer Res. (1991) 51: 4149–4154.
   PubMed Web of Science ®Google Scholar
• LEMOINE NR, JAIN S, SILVESTRE F, LOPES C, HUGHES CM, MCLELLAND E, GULLICK WJ, FILIPE MI: Amplification and overexpression of the EGF receptor and c-erbB-2 prow-oncogenes in human stomach cancer. Brit. J Cancer (1991) 64:79–83.
   PubMedGoogle Scholar
• LEMOINE NR, STADDON S, DICKSON C, BARNES DM, GULLICK WJ: Absence of activating transmetnbrane mu-tations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene (1990) 5:237–239.
   PubMed Web of Science ®Google Scholar
• LEOPOLD WR, PRZYBRANOWSKI SA, HOOK KE, AM- BROSO L, FRY DW: Modulation of the growth inhibitory properties of a novel class of protein tyrosine kinase Inhibitors, the 2-thioindoles, by physiological concen-trations of g,lutathione. Proc. Am. Assoc. Cancer Res. (1993) 34:408.
   Google Scholar
• LEVITZKI A, GILON C: Tyrphostins as molecular tools and potential antiproliferative drugs. Trends Pharmacol. Sci. (1991) 12:171–174.
   PubMed Web of Science ®Google Scholar
• LEVITZKI A: Tyrphostins: tyrosine kinase blocicers as novel antiproliferative agents and dissectors of signal transduction. FASEB (1992) 6:3275–3282.
   PubMed Web of Science ®Google Scholar
• LEWIS S, LOCKER A, TODD JH, BELL JA, NICHOLSON R, ELSTON CW, BLAMEY RW, ELLIS JO: Expression of epi-dermal growth factor receptor in breast carcinoma. J. Clin. Pathol. (1990) 43:385–389.
   PubMed Web of Science ®Google Scholar
• LIBBY P, SCHWARTZ D, BROGI E, TANAKA H, CLINTON SK: A cascade model for restenosis - a special case of atherosclerosis progression. Circulation (December 1992) 86:47–52.
   PubMed Web of Science ®Google Scholar
• LIBERMAN TA, RAZON N, BARTAL AD, YARDEN Y, SCHLESSINGER J, SOREQ H: Expression of epidermal growth factor receptors in human brain tumors. Cancer Res. (1984) 44:753–760.
   PubMed Web of Science ®Google Scholar
• LIBERMANN TA, NUSBAUM HR, RAZON N, KRIS R, LAX I, SOREQ H, WHITTLE N, WATERFIELD MD, ULLRICH A, SCHIESSINGER J: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin. Nature (1985) 313:144–147.
   PubMed Web of Science ®Google Scholar
• LIBERT C, VINK A, COULlE P, BROUCKAERT P, EVERAERDT B, VAN SNICK J, HERS W: Limited involvement of inter-leukin 6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin 6 or its receptor in various murine models. Eur J.Immunol. (1992) 22: 2625–2630.
   PubMed Web of Science ®Google Scholar
• LIDEREAU R, CALLAHAN R, DICKSON C, PETERS G, ESCOT C, ALI IU: Amplification of the int-2 gene in primary human breast tumors. Oncogene Res. (1988) 2:285–291.
   PubMedGoogle Scholar
• LIEBERMAN AP, PITHA PM, SHIN HS, SHIN ML: Production of tumor necrosis factor and other cytokines by astro-cytes stimulated with lipopolysaccharide or a neurotropic virus. Proc.Natl.Acad.Sci.(USA) (1989) 86: 6348–6352.
   PubMed Web of Science ®Google Scholar
• LIEBL EC, MARTIN GS: Intracellular targeting of pp6Osrc expression - localization of v-src to adhesion plaques is sufficient to transform chicken embryo fibroblasts. Oncogene (1992) 7:2417–2428.
   PubMed Web of Science ®Google Scholar
• LINDEMANN CB, KANOUS KS: Regulation of mammalian sperm motility. Arch. AndroL (1989) 23:1–22.
   PubMed Web of Science ®Google Scholar
• LISCIA DS, MERLO GR, GARRETT C, FRENCH D, MARIANI-COSTANTINI R, CALLAHAN R: Expression of Oa-2 mRNA In human tumors amplified at the int-2 locus. Oncogene (1989) 4:1219–1224.
   PubMed Web of Science ®Google Scholar
• LISSONI P, BARNI S, ROVELLI F, TANCINI G: Lower sur-vival in metastatic cancer patients with reduced inter-leukin- 2 blood concentrations Oncology (1991) 48:125–127.
   Google Scholar
• LIU C, TSAO MS: In vitro and in vivo expressions of transforming growth factor-alpha and tyrosine kinase • receptors in human non-small-cell lung carcinomas. Amer. J. Pathol. (1993) 142:1155–1162.
   PubMed Web of Science ®Google Scholar
• LOCKWOOD JL, SENYEI AE, DISCHE MR, CASAL D, SHAH KD, THING SN, JONES L, DELIGDISCH L, GARTTE TJ: Foetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. New Engl. J. Med. (1991) 325:669–674.
   PubMed Web of Science ®Google Scholar
• Evaluation of local fibronectin concentrations as an early detection parameter for chorioamnionitis.
   Google Scholar
• LOPEZ M, CARPANO S, CANCRINI A, MAECELLINI M, DEL-• MEDICO M, RINALDI M, VICI P: IL-2 by continuous intra-venous infusion in advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. (1993) 12:792.
   Google Scholar
• LOPEZ-HANNINEN E, KORFER A, HADAM M, SCHNEEK-LOTH C, DALLMANN I, MENZEL T, KIRCHNER H, POLI-VMDA H, ATZPODIEN J: Biological monitoring of low-dose Interleuicin-2 in humen: Soluble interleukin-2 receptors, cytolcines, and cell surface phenotypes. Can-cer Res. (1991) 50:6312–6316.
   Google Scholar
• LOTZE MT, GRIMM EA, MAZUMDER EA, STAUSSER ROSENBERG SA: Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell-growth factor. Cancer Res. (1981) 41:4420–4425.
   PubMed Web of Science ®Google Scholar
• LOTZOVA E, SAVARY C, ICEATING M: Studies on the mechanism of defective natural killing in leukemia-dis-eased patients. Exp. Hematol. (1982) 10:83–88.
   Web of Science ®Google Scholar
• LUGO TG, PENDERGAST AM, MULLER AJ, WI= ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science (1990) 247:1079–1082.
   PubMed Web of Science ®Google Scholar
• LUNDY J, SCHUSS A, STANICK D, MCCORMACK ES, KRA-/VIER S, SORVILLO JM: Expression of neu protein, epider-mal growth factor receptor, and transforming growth factor-alpha in breast cancer - correlation with clinico-pathologic parameters. Amer. J. Pathol. (1991) 138:1527–1534.
   PubMed Web of Science ®Google Scholar
• LUNENFELD B, INSLER V: Infertilhy: the dimension of the problem. In: infertility. Male and Female. (1993) Lun-enfeld B, Insler V (Eds) Churchill Livingstone, Edinburgh pp 3–7.
   Google Scholar
• A detailed review of published figures for the prevalence of infertility and the frequency of occurrence of the different sub-types.
   Google Scholar
• LUPU R, COLOMER R, KANNAN B, LIPPMAN ME: Charac-terization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. Proc. Natl. Acad. Sci. USA (1992) 89:2287–2291.
   PubMed Web of Science ®Google Scholar
• LUPU R, LIPPMAN ME. The role of erbB2-signal transduc-tion pathways in human breast cancer. Breast Cancer Res. Treat. (1993) 27:83–93
   PubMed Web of Science ®Google Scholar
• LUTTRELL DK, LEE A, LANSING TJ, CROSBY EM, JUNG kD, VUILLARD D, LUTHER M, RODRIGUEZ M, BERMAN J, GIL-MER TM: Involvement of pp6Osrc with two major sig-naling pathways in human breast cancer. Proc. Natl. Acad. Sci. USA (1994) 91:83–87.
   PubMed Web of Science ®Google Scholar
• LYNCH DH, NAMEN AE, MILLER RE: In vivo evaluation of the effects of interleulcin-2, -4, and -7 on enhancing theimmunotherapeutic efficiacy of antitumor cytotoxic T lymphocytes. Europ. J. ImmunoL (1991) 21:2977–2985.
   PubMed Web of Science ®Google Scholar
• MACARTHUR LH, CLARICE MF, WESTIN EH: Malignant transformation of NIEL 3t3 fibroblasts by human c-sis is dependent upon the level of oncogene expression. Mol. Carcinogen. (1992) 5:311–319.
   PubMed Web of Science ®Google Scholar
• MACIAS A, AZAVEDO E, HAGERSTROM T, KLINTENBERG C, PEREZ R, SKOOG L: Prognostic significance of the receptor for epidermal growth factor in human mam-mary carcinomas. Anticancer Res. (1987) 7:459–464.
   PubMed Web of Science ®Google Scholar
• MALIK R, GOPE M, WOMER RB, NAGASHUNMUGAM T, MARG OLIN JF, BASU A, SCHER CD: Structure and expres-sion of the beta-platelet- derived growth factor receptor gene in human tumor cell lines. Cancer Research (1991) 51:5626–5631.
   PubMed Web of Science ®Google Scholar
• MANDANAS RA, LEIBOWITZ DS, GHAREHBAGHI K, TAUCHI T, BURGESS GS, MIYAZAWA K, JAYARAM HN, BOS WELL HS: Role of p21 RAS in p210 bcr-abl transfor-mation of murine myeloid cells. Blood (1993) 82: 1838-1847.
   Google Scholar
• MANDELLI F, TRIBALTO M, AVVISATI G: Recombinant Interferon- alpha-2b as post-induction therapy for re-sponding multiple myeloma patients. Cancer Treatm. Rev. (1988) 15:43–48.
   PubMed Web of Science ®Google Scholar
• MANNING M, SAWYER WH: Discovery, development and some uses of vasopressin and oxytocin antagonists. j Lab. Clin. Med. (1989) 114:617–632.
   PubMed Web of Science ®Google Scholar
• MARCOZ P, NEMOZ G, PRIGENT AF, LAGARDE M: Phos- phatidic acid stimulates the rolipram-sensitive cyclic nucleotide phosphodiesterase from rat thymocytes. Biochim.Biophys.Acta (1993) 1176: 129–136.
   PubMed Web of Science ®Google Scholar
• MARTINEZ OM, GIBBONS RS, GAROVOY MR, ARONSON FR: 114 inhibits IL-2 receptor expression and IL-2-de-pendent proliferation of human T cells. J. Immunol. (1990) 144:2211–2215.
   PubMed Web of Science ®Google Scholar
• MARU Y, WITTE ON: How does the chimeric BCR-ABL oncogene function in human chronic myelogenous leukemia. In: Application of Basic Science to Hematopoiesis and Treatment of Disease? Thomas ED (Ed) Raven Press, New York 1993 pps 123–143.
   Google Scholar
• Excellent review on the contribution of the BCR-ABL oncogene to chronic myelogenous leukemia.
   Google Scholar
• MARU Y, WI1Th ON: The BCR gene encodes a novel serine/ threonine kinase activity within a single exon. Cell (1991) 67: 459–468.
   PubMed Web of Science ®Google Scholar
• MASHl H, ICAWAMOTO T, SATO JD, WOLF B, SATO G, MENDELSOHN J: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. (1984) 44:1002–1007.
   PubMed Web of Science ®Google Scholar
• MASUI H, MOROYAMA T, MENDELSOHN J: Mechanism of antitumor activity in mice for anti-epkiermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res. (1986) 46:5592–5598.
   PubMed Web of Science ®Google Scholar
• MATSUYOSHI N, HAMAGUCHI M, TANIGUCHI S, NA-GAFUCHI A, TSUKITA S, TAKEICHI M: Cadherin-mediated cell-cell adhesion is perturbed by v-src tyrosine phos-phorylation in metastatic fibroblasts. J. Cell Biol. (1992) 118:703–714.
   PubMed Web of Science ®Google Scholar
• MAXWELL SA, SACKS PG, GUTTERMAN JU, GALLICK GE: Epidermal growth factor receptor protein-tyrosine ki-nase activity in human cell lines established from squamous cardnomas of the head and neck. Cancer Res. (1989) 49:1130–1137.
   PubMed Web of Science ®Google Scholar
• MCADAM, ET AL.: Coexpression of interleukin-2 and gamma-interferon enhances tumor immunity. Ann. NY • Acad. Sci. (1993) 690:349–351.
   Google Scholar
• MCBRIDE 'OM, ECONOMOU JS, NAYERSINA R, COMORA S, ESSNER R: Influence of interleukins 2 and 4 on tumor necrosis factor production by murine monocular phagocytes. Cancer Res. (1990) 50:2949–2957.
   PubMed Web of Science ®Google Scholar
• MCCABE MS, STABLEIN D, HAWKINS MJ: The modified group c experience- phase HI randomized trials of I1-2 vs IL-2/LAK in advanced renal cell carcinoma and advanced melanoma. Proc. Am. Soc. Clin. Oncol. (1991) 10:714.
   Google Scholar
• MCGREGOR JA, FRENCH JI, KYUNG SEO: Antimicrobial therapy in preterm premature rupture of membranes: Results of a prospective, double blind placebo control-led trial of erythromycin. Am. J. Obstet. GynecoL (1991) 165:632-640 [391 and [401 are studies dealing with the possibilities of systemic antibiotic therapy in preterm labour/premature rupture of mem-branes.
   Google Scholar
• MCGREGOR JA, FRENCH JI, RELLER LB: Adjunctive erythromycine treatment for idiopathic preterm labor: Results of a prospective, double-blind, placebo control-led trial. Am. J. Obstet. Gynecol. (1986) 154:98–103.
   PubMed Web of Science ®Google Scholar
• MCINTOSH JK, MULE JJ, KROCNICK JA, ROSENBERG SA: Combination cytokine immunotherapy with tumor ne-crosis factor alpha, interleukin-2 and its synergistic antitumor effects in mice. Cancer Res. (1989) 29:1408–1414.
   Google Scholar
• MCINTOSH JK, MULE JJ, MERINO MJ, ROSENBERG SA: Synergistic antitumor effects of immunotherapy with recombinant tumor necrosis factor-alpha. Cancer Res. (1988) 48:4011–4017.
   PubMed Web of Science ®Google Scholar
• MCWHIRTER JR, WANG JYJ: Activation of tyrosine kinase and microfllament-binding functions of c-abl by bcr sequences in bcriabi fusion proteins. MoL Cell. Biol. (1991) 11:1553–1565.
   PubMed Web of Science ®Google Scholar
• MELIN P, TROJNAR JJOHANSSON B, VILHARDT H, AICER-LUND M: Synthetic antagonists of the myometrial re-sponse to vasopressin and oxytocin. J. Endocrinol. (1986) 111:125–131.
   PubMed Web of Science ®Google Scholar
• MELIN, P. Oxytockc antagonists and their therapeutic use. Regulatory Peptides (1993) 45:285–288.
   PubMed Web of Science ®Google Scholar
• METCALF D: Control of granulocytes and macrophages: molecular, cellular, and clinical aspects. Science (1991) 254: 529–533.
   PubMed Web of Science ®Google Scholar
• MEURER LC, TOLMAN RE, CHAPIN EW, SAPERSTEIN R, VICARIO PP, ZRADA M, MACCOSS M: Synthesis and hy-poglycaemic activity of substituted 8-(1-Piperaz-inyDimidazof1,2-a]pyrazines. J. Med. Chem. (1992) 35:3845–3857.
   PubMed Web of Science ®Google Scholar
• MILLER RE: Pancreatic neuroendocrinology: peripheral neural mechanisms in the regulation of the islets of Langerhans. Endocrine Rev. (1981) 2:471–494.
   PubMed Web of Science ®Google Scholar
• MIZUTANI T, ONDA M, TOKUNAGA A, YAMANAICA N, SUGISAKI Y: Relationship of c-erbB-2 protein expres-sion and gene amplification to invasion and metastasis In human gastric cancer. Cancer (1993) 72:2083–2088.
   PubMed Web of Science ®Google Scholar
• MODJTAHEDI H, DEAN C: The receptor for EGF and its lig-ands - expression, prognostic value and target for therapy in cancer. Intl. Oncol. (1994) 2:277–296.
   Google Scholar
• Most up to date review on the involvement of the EGF receptor in human cancer.
   Google Scholar
• MODJTAHEDI H, ECCLES S, BOX G, STYLES J, DEAN C: Immunotherapy of human tumour xenografts °verde-pressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br. J. Cancer (1993) 67:254–261.
   PubMed Web of Science ®Google Scholar
• MOOLENAAR WH, ICRUIJER W, TILLEY BC, VERLAAN I, BIERMAN A, DELAAT SW: Growth factor-like action of phosphatidic acid. Nature (1986) 323:171–173.
   PubMed Web of Science ®Google Scholar
• MOORE MAS: Clinical implications of positive and nega-tive hematopoietic stem cell regulators. Blood (1991) 78: 1–19.
   PubMed Web of Science ®Google Scholar
• MOORE R, CASEY G, BROOKES S, DIXON M, PETERS G, DICKSON C: Sequence topography and protein coding potential of mouse int-2: a putative oncogene activated by mouse mammary tumour virus. EMBOJ. (1986) 5:919–924.
   PubMed Web of Science ®Google Scholar
• MORGAN DA, RUSCETTI FW, GALLO RC: Selective in vitro growth of T lymphocytes from normal human bone marrows. Science (1976) 192:1007–1012.
   PubMedGoogle Scholar
• MORGAN NG, CHAN SLF, LACEY RJ, BROWN CA: The pharmacology and molecular biology of islet cell ad-renoceptors. In: Frontiers of Pancreatic B-Cell Research (1994) Springer International, In press
   Google Scholar
• MORGAN NG, HURST RD, CHAN SLF: Control of insulin secretion by az-adrenergic receptor activation. Proc 5th Japan a-Receptor Conf (1989) (Excerpta Medico., Tokyo) pp 79–96.
   Google Scholar
• MORGAN NG: Regulation of insulin secretion by az-ad-..renergic agonists. Trends Pharmacol. Sci. (1987) 8:369–370.
   Web of Science ®Google Scholar
• MORISHIGE K, KURACHI H, AMEMIYA K, ADACHI H, INOUE M, MIYAKE A, TANIZAWA O, SAKOYAMA Y: In-volvement of transforming growth factor-alpha/epi-dermal growth factor receptor autocrine growth mechanism in an ovarian can cell line in vitro. Cancer Res. (1991) 51:5951–5955.
   PubMed Web of Science ®Google Scholar
• MORLEY JE, MEYER N, PEKARY AE, MELMED S, CARLSON HE, BRIGGS JE, HERSHMAN JM: A prolactin inhibitory factor with immuno-characteristics similar to thy-rotropin-releasing hormone (TRH) is present in rat pituitary tumors (GH3 and W5), testicular tissue and a plant material, alfalfa. Biochem. Biophys. Res. Commun. (1980) 96:47–53.
   PubMed Web of Science ®Google Scholar
• MORRELL JM, CURRY MR, WATSON PF, MALONE PR, COCKLE SM: The TRH-like peptide pG1u-Glu-ProN112 is present in human prostate and may affect sperm mo-tility. J. Rep rod. Fert. (1991) Abstract Series 7:23.
   Google Scholar
• First preliminary evidence that FPP may affect sperm function, in particular causing a slight stimulation of sperm motility.
   Google Scholar
• MOSMANN TR, BOND MW, COFFMAN RL, OHARA J, PAUL WE: T cell and mast cell lines respond to B cell stimula-tory factor-1. Proc. Nat. Acad. Sci. USA (1986) 83:5654.
   PubMed Web of Science ®Google Scholar
• Moxey-Mims MM, Simms H, Frank MM, Lin EY, Gaither TA: The effects of 11-1, IL-2, and tumor necrosis factor on polymorphonuckar leukocytes Pc gamma receptor- mediated phagocytisis:IL-2 downregulates the effect of tumor necrosis factor. J. Immunol. (1991) 147:1823–1830.
   PubMed Web of Science ®Google Scholar
• MUKAIDA H, TOI M, HIRAI T, YAMASHITA Y, TOGE T: Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer (1991) 68:142–148.
   PubMed Web of Science ®Google Scholar
• MULE J[J, SMITH GRAIG A, ROSENBERG SA: Interleukin-4 can mediate the induction of lymphokin-activated kil-ler cell activity directed against fresh tumor cells. J. Exp. Med. (1987.) 166:792–797.
   PubMedGoogle Scholar
• MULLER AJ, YOUNG JC, PENDERGAST AM, PONDEL M, LANDAU NR, LITTMAN DR, wirrE ON: BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol. Cell. Biol. (1991) 11: 1785–1792.
   PubMed Web of Science ®Google Scholar
• MULLER WJ, SINN E, PAI1ENGALE PK, WALLACE R, LEDER P: Single-step induction of mammary adenocarcinoma In transgenic mice bearing the activated c-neu onco-gene. Cell (1988) 54:105–115.
   PubMed Web of Science ®Google Scholar
• MURAICAMI Y, MIZUNO S, HORI M, UEHARA Y: Reversal of transformed phenotypes by herbinzycin A in src oncogene expressed rat fibroblasts. Cancer Res. (1988) 48:1587–1590.
   PubMed Web of Science ®Google Scholar
• MURAYAMA T, UI M: Phosphatidic add may stimulate membrane receptors mediating adenylate cyclase inhi-bition and phospholipid breakdown in 3T3 fibroblasts. J.Biol.Chem. (1987) 262: 5522–5529.
   PubMed Web of Science ®Google Scholar
• MURRAY C, HAVERKAMP AD, ORLEANS M, BERGA S, PECHT D: Nifedipine for treatment of preterm labour: a historic prospective study. Am. J. Obstet. Gynecol. (1992) 167(1):52–56.
   PubMed Web of Science ®Google Scholar
• MURRAY JL, PILLOW JK, ROSENBLUM MG: Differential in vitro effects of alpha recombinant interferon andgamma recombinant interferon on the expression of melanoma-associated antigens. Proc. Am. Assoc. Cancer Res. (1986) 27:313.
   Web of Science ®Google Scholar
• MURRAY JL, PILLOW JK, ROSENBLUM MG: Differential in vitro effects of recombinant alpha-interferon and re-combinant gamma- interferon on the expression of melanoma-associated antigens. Proc. Amer. Assoc. Cancer Res. (1986) 27:313.
   Web of Science ®Google Scholar
• MUSS FIB: Interferon therapy for renal cell carcinoma. Sem. Oncol. (1987) 15:36–42.
   Google Scholar
• MUSS HB: Interferon therapy for renal cell carcinoma. Sem. Oncol. (1987) 15:36–42.
   Google Scholar
• MUTHUSWAMY SK, SIEGEL PM, DANKORT DL, WEBSTER MA, MULLER WJ: Mammary tumors expressing the neuproto-oncogene possess elevated c-arc tyrosine kinase activity. Mol. Cell. Biol. (1994) 14:735–743.
   PubMed Web of Science ®Google Scholar
• NAIR RMG, BARRETT JF, BOWERS CY, SCHALLY AV: Struc-ture of porcine thyrotropin-releasing hormone. Bio-chem. (1970) 9:1103–1106.
   Google Scholar
• NARUMI S, FINKLE JH, HAMILTON TA: Interferon-gamma and interleukin-2 synergize to induce selective monok-ine expression in murine pertoneal macrophages. J. Biol. Chem. (1990) 265:7036–7041.
   PubMed Web of Science ®Google Scholar
• NATHAN CF, MURRAY HW, WIEBE ME: Identification of Interferon- gamma as the lymphokine that activates human macrophage oxidative metabolism and antimi-crobial activity. J. Exp. Med. (1983) 158:670–689.
   PubMed Web of Science ®Google Scholar
• NEAL DE, MARSH C, BENNETT MK, ABEL PD, HALL RR, SAINSBURY JRC, HARTS AL: Epidermal growth factor receptors in human bladder cancer: comparisons of invasive and superficial tumors. Lancet (1985) 1:366–368.
   PubMed Web of Science ®Google Scholar
• NEDWIN GE, SVEDERSKY LP, BRINGMAN TS, PALLADINO MA, GOEDDEL DV:Effect of interleuldn-2, interferon -gamma, and mitogens on the production of tumor necrosis factor alpha and beta. J. Immunol. (1985) 135:2492–2497.
   PubMed Web of Science ®Google Scholar
• NEGRIER S, PHILIP T, STOTER G, FRANKS CR: Interieukin-2 with or without lak cells in metastatic renal cell carcinoma: A report of a European multicenter study. Europ. J. Cancer Clin. Oncol. (1989) 25:21–28.
   Google Scholar
• NELSON JM, AMBROSO LA, FRY D'37: Specific inhibition of bFGF- mediated tyrosine phosphorylation in fi-broblasts treated with 2- thioindoes, a new structural class of tyrosine kinase inhibitors. Proc. Am. Assoc. Cancer Res. (1993) 34:408.
   Google Scholar
• NEMUNAITIS J, ROSENFELD C, ASH R, FLOMENBERG N, FRIEDMAN M, DEEG J, APPELBAUM F, SINGER JW, DALTON W, ELFENBEIN G, RIFKIN R, RUBIN A, AGOSTI J, HAYES EA, SHADDUCK RK: Phase Ill double-bind trial of rhGM-CSF (Sargramostin) following allogeneic bone marrow transplant (BMT). Blood (1994) 82: 286A. (Abstr.)
   Google Scholar
• NETAJI B, MURTHY S, BUDD GT, FINER J, HERZOG P, STANLEY J, SERGI J, TUBBS R, BAUER L, BUKOWSKI RM: Phase IA/B trial of interleukin-2 and interleulcin-4 on refractory malignancy: Toxicity and immunologic changes: Proc. Am. Assoc. Cancer Res. (1991) 32:193.
   Google Scholar
• NEUFELD G, MITCHELL R, PONTE P. GOSPODAROWICZ D: Expression of human bask fibroblast growth factor cDNA in baby hamster kidney-derived cells results in autonomous cell growth. J. CellBiol. (1988) 106:1385–1394.
   Google Scholar
• NICHOLSON S, RICHARD J, SAINSBURY C, HALCROW P, KELLY P, ANGUS B, WRIGHT C, HENRY J, FARNDON JR, HARRIS AL: Epidermal growth factor receptor (EGFr), results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br. J. Cancer (1991) 63:146–150.
   PubMed Web of Science ®Google Scholar
• NIDDAM R, ANGEL I, BIDET S, LANGER SZ: Pharmacologi-cal characterization of alpha-2 adrenergic receptor sub-type involved in the release of insulin from isolated rat pancreatic islets. J. Pharrnacol. Exp. Ther. (1990) 254:883–887.
   PubMed Web of Science ®Google Scholar
• This describes the first evidence that insulin secretion is controlled by an cc2A-adrenoceptor in rodent islets.
   Google Scholar
• NISHIMURA T, OHTA S, SATO N, TOGASHI Y, GOTO M, HAHIMOTO Y: Combination tumor-immunotherapy with recombinant tumor necrosis factor and recombi-nant interleukin 2 in mice. Intern. J. Cancer (1987) 40:255–261.
   PubMed Web of Science ®Google Scholar
• NOGUCHI M, YOSHIAKI N, RUSSEL SM, ZIEGLER SF, TSANG M, GAO X, LEONARD WJ: Interleukin-2 receptor gamma-0121n- a functional component of the Inter-leukin-7 receptor. Science (1993) 262: 1877-1880.
   Google Scholar
• NOMURA Y, KITAMLTRA Y, TOHDA M, TOKUMITSU Y: Drugs acting on the intracellular signaling system. Medicinal Research Reviews (1993) 13:1–60.
   PubMed Web of Science ®Google Scholar
• OH-SHI T, GOLDMAN CK, MIST1 J, WALDMANN TA: The Interaction of interleukin-2 with its receptor in the generation of suppressor T cells in the antigen-specific and antigen-nonspecific system its vitro. Clin. Immunol. Immunopathol. (1989) 52:447–459.
   PubMedGoogle Scholar
• OHNEDA K, OHNEDA A, KOIZUMI F: Mechanism of Insulin secretion by raidaglizole. Diabetes Res. Clin. Prac. (1993) 19:127–132.
   PubMed Web of Science ®Google Scholar
• OIKKANEN S, HELIN H, ISOLA J, JOENSUU H: Prognostic significance of HER-2 oncoprotein expression in breast cancer - a 30-year follow-up. J. Clin. Oncol. (1992) 10: 1044–1048.
   PubMed Web of Science ®Google Scholar
• OKABE M, UEHARA Y, MIYAGISHIMA T, ITAYA T, TANAKA M, KUNIEDA Y, KUROSAWA M, MIYAZAKI T: Effect of herbimycin-A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations - ab-rogative effect on the transformation of murine he-matopoietic cells by transfection of a retroviral vector expressing oncoprotein p210(ber/abl) and preferential Inhibition on Ph(1)-positive leukemia cell growth. Blood (1992) 80:1330–1338.
   PubMed Web of Science ®Google Scholar
• OKAMURA N, SUGITA Y: Activation of spermatozoan adenylate cyclase by a low molecular weight factor in porcine seminal plasma. J. Biol. Chem. (1983) 258:13056–13062.
   PubMedGoogle Scholar
• OKUSAWA S, GELFAND JA, IKEJIMA T, CONNOLLY RJ, DINARELLO CA: Interleukin 1 induces a shock like state In rabbits. J. Clin invest. (1988) 81: 1162–1172.
   PubMed Web of Science ®Google Scholar
• OLDHAM R, CHURCH C, ARNOLD J: Cancer Biotherapy: Insights into activated cellular therapy. Proc. Am. Soc. Clin. Oncol. (1993) 12:962.
   Google Scholar
• OLENCKI T, NATAJI B, BLTDD GT, FINER J, MURTHY S, HERZOG P, TUI3BS R, THOMASSEN MJ, BAITER L, SERGI JS, BUKOWSKI RM: Phase 1 trial of rIL-2 and rhu1L-4 in patients with refractory malignancy: Hematologic and Immunologic effects. Blood (1991) 78:439a.
   Google Scholar
• ONO S, TOMIKAWA M: a-Adrenergic hyper-responsive-ness in diabetic A-ICK mice. In: Lessons from Animal Diabetes H (1987) p331.
   Google Scholar
• ONODA T, IINUMA H., SASAKI Y, HAMADA M, ISSHIKI K, NAGANA'WA H, TAICEUCI-II T: Isolation of a novel tyro-sine kinase inhibitor, lavendustin A, fromStreptomyces griseolavendus. J. Nat. Prod. (1989) 52:1252–1257.
   PubMed Web of Science ®Google Scholar
• ONODA T, ISSHIKI K, TAKEUCHI T, TATSUTA K, UMEZAWA K: Inhibition of tyrosine kinase and epider-mal growth factor receptor internalization by laven-dustin A methyl ester in cultured A431 cells. Drugs Papa. Clin. Res. (1990) 16:249–253.
   PubMed Web of Science ®Google Scholar
• OSHEROV N, GAZIT A, GILON C, LEVITZKI A: Selective inhibition of the epidermal growth factor and ber2Inese receptors by tyrphostins. J. Biol. Chem. (1993) 268:11134–11142.
   PubMed Web of Science ®Google Scholar
• Demonstration of inhibitory discrimination between EGF receptor and erbB-2.
   Google Scholar
• OSMAN RA, ANDRIA ML, JONES AD, MEIZEL S: Steroid Induced exocytosis: the human sperm acrosome reac-tion. Biochem. Biophys. Res. Commun. (1989) 160:828–833.
   PubMed Web of Science ®Google Scholar
• OSTENSEN ME, THIELE DL, LIPSKY PE: Tumor necrosis factor-alpha enhances cytolytic activity of human natu-ral killer cells. J. Immunol. (1987) 138:4185–4191.
   PubMed Web of Science ®Google Scholar
• OIIENHOFFICALFF AE, RIJKSEN G, VANBEURDEN EACM, HENNIPMAN A, MICHELS AA, STAAL GEJ: Charac-terization of protein tyrosine kinases from human breast cancer - involvement of the c-arc oncogene product. Cancer Res. (1992) 52:4773–4778.
   PubMed Web of Science ®Google Scholar
• OTTESEN SS, AHRENKIEL V, K1ELER J: Recombinant hu-man gamma- interferon exerts an antiproliferative fect and modulates the expression of human leuko-cytes antigens A, B, C, and DR. Cancer Immunol. Immu-noth. (1990) 31:93–98.
   PubMed Web of Science ®Google Scholar
• OWEN-SCHAUB LB, GU ri ERMAN JU, GRIMM EA: Synergy of tumor necrosis factor and interleukin-2 in activation of human cytotoxic lymphocytes. Cancer Res. (1988) 48:788–792.
   PubMed Web of Science ®Google Scholar
• OWEN-SCHAUB LB, GUTTERMAN JU, GRIMM EA: Synergy of tumor necrosis factor and interleukin 2 in the acti-vation of human cytotoxic lymphocytes: Effect of tumor necrosis factor and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Res. (1988) 48:788–792.
   PubMed Web of Science ®Google Scholar
• PACE JL, RUSSELL SW, TORRES BA, JOHNSON HM, GRAY PW: Recombinant mouse gamma-interferon induces the priming step in macrophage activation for tumor cell killing. J. Immunol. (1983) 130:2100–2013.
   Google Scholar
• PAIEC SM: Clinical significance of erbB2 (ber-2/neu) protein. Cancer Invest. (1992) 10:575–579.
   PubMed Web of Science ®Google Scholar
• PALMER PA, VINKE J, EVERS P, POURREAU C, OSKAM R: Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine-activated killer cells for the treatment of advanced renal cell carcinoma. Europ. J. Cancer (1992) 28a:1038–1044.
   Google Scholar
• PANAYOTOU G, WATERFIELD MD: The assembly of sig-naling complexes by receptor tyrosine kinases. Bioes-says (1993) 15:171–177.
   PubMed Web of Science ®Google Scholar
• PAOLOZZI F, ZAMKOFF K, DOYLE M, KONRAD M, BRADLEY EC, RUDOLPH A, NEWMAN N, GULLO J, SZALO A, POIESZ B: Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplas-tic diseases- J. Biol. Resp. Modifiers (1989) 8:122–139.
   PubMedGoogle Scholar
• PEKARY AE, MEYER NV, VAILLANT C, HERSHMAN JM: Thyrotropin-releasing hormone and a homologous peptide in the male reproductive system. Biochem. Bio-phys. Res. Commun. (1980) 95:993–1000.
   PubMed Web of Science ®Google Scholar
• The first report of a TRH-like peptide with different chromatographic properties from authentic TRH in male reproductive tissues.
   Google Scholar
• PEKARY AE, ROSEN JI, GEOLA F, VAILLANT C, SHARP B, MEYER N, HERSHMAN JM: Thyrotropin-releasing hor-mone and a homologous peptide in the reproductive system of the female rat and pig. Biochem. Biophys. Res. Commun. (1981) 99:73–80.
   PubMed Web of Science ®Google Scholar
• PELES E, YARDEN Y. Neu and its ligands: From an oncogene to neural factors. BioEssays (1993) 15:815–824.
   PubMed Web of Science ®Google Scholar
• Excellent article reviewing recent infomation of ligands for erbB-2.
   Google Scholar
• PENDERGAST AM, MULLER AJ, HAVL1K MH, CLARK R, MCCORMICK F, WITTE ON: Evidence for regulation of the human abl tyrosine kinase by a cellular inhibitor. Proc. Nat. Acad. Sci. USA (July 1991) 88:5927–5931.
   PubMed Web of Science ®Google Scholar
• PENDERGAST AM, MULLER AJ, HAVLIK MM, MARU Y, WITTE ON: BCR sequences essential for transformation by the bcr-abl oncogene bind to the abl-S112 regulatory domain in a non-phosphotyrosine- dependent manner. Cell (1991) 66:161–171.
   PubMed Web of Science ®Google Scholar
• PETTIBONE DJ, CLINESCHMIDT By, ANDERSON PS: A structurally unique, potent and selective oxytocin an-tagonist derived from Streptomyces silvensis. Endocri-nology(1989) 125:217-222. [23-25] present the first clinical applicable oxytocin antagonists with peptidyl structure.
   Google Scholar
• PETTIBONE DJ, CLINESCHMIDT By, KISHEL MT, US EV, REISS DR, WOYDEN CJ, EVANS BE, FREIDINGER RM, VE-BER DF, COOK MJ, HALUSKA GJ, NOVY MJ, LOWENSOHN RI: Identification of an orally active, nonpeptidyl oxy-tocin antagonist J. Pharmacol. Exp. Ther. (1993) 264.
   Google Scholar
• First publication of an orally active oxytocin antagonist.
   Google Scholar
• PHILIP T, NEGREER S, LASSET C, CORONEL B, BRET M, BLAY JY, MERROUCHE Y, CARRIE C, KAEMMERLEN P, CHAUVIN F, FAVROT M, OSICAM R, TABAH I, CLAVEL M, MOSKOVTCHENKO JF, MERCATELLO A: Patients with metastatic renal carcinoma candidate for iaununo-therapy with cytokines. Analysis of a single institution study on 181 patients. Br. J. Cancer (1993) 68:1036–1042.
   Google Scholar
• PHILLIPS JH, GEMLO BT, MYERS WW, RAYNER AA, LANIER LL: In vivo and in vitro activation of natural killer cells In advanced cancer patients undergoing combined re-combinant interleukin-2 and IAK cell therapy. J. Clin. Oncol. (1987) 5:1933–1941.
   PubMed Web of Science ®Google Scholar
• PICHERT G, JOST LM, FTERZ W, STAHEL RA: Clinical and immune modulatory effects of alternative weekly inter-leukin-2 and interferon-alpha-2a in patients with ad-vanced renal cell carcinoma and melanom. Br.J. Cancer (1991) 63:287–292.
   PubMed Web of Science ®Google Scholar
• PLANT TD, JONAS JC, HENQUIN JC: Clonidine inhibits ATP-sensitive potassium channels in mouse pancreatic fl-cells. Br.J. Pharmacol. (1991) 104:385–390.
   PubMed Web of Science ®Google Scholar
• Direct demonstration that clonidine has actions on islet cell KATP channels that are not due to u2-agonism.
   Google Scholar
• PRIGENT SA, LEMOINE NR: The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog. Growth Factor Res. (1992) 4:1–14.
   PubMedGoogle Scholar
• PROUTEAU M, LEVRIER J, ANGEL I: Effects of the anti-dia-betic alpha-2 adrenoceptor antagonist SL 84.0418 on plasma glucose and insulin levels following exercise in normal and type II diabetic rats. Diabetologia (1992) 35\(Supp1.1):A104.
   Google Scholar
• PRUMMER O, FRICKHOFEN N, DIGEL W, HEMPEL H, PORZSOLT F: Spontaneous interferon- alpha antibodies In a patient with pure red cell aplasia and recurrent cutaneous carcinomas. Ann. Hematol. (1991) 62:76–80.
   PubMed Web of Science ®Google Scholar
• PURI PK, LELAND P: In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-acti-vated killer cells in the organs of mice. Clin. Exp. Immunol. (1991) 85:317–325.
   PubMed Web of Science ®Google Scholar
• PURI RK, TRAVIS WD, ROSENBERG SA: In vivo admini-stration of interferon alpha and interleukin-2 induces proliferation of lymphoid cells in the organs of mice. Cancer Res. (1990) 50:5543–5550.
   PubMed Web of Science ®Google Scholar
• PURI RK, TRAVIS WD, ROSENBERG SA: In vivo admini-stration of interferon-alpha and interleukin-2 induces proliferation of lymphoid cells in the organs of mice. Clin. Exp. Immunol. (1991) 85:317–325.
   PubMed Web of Science ®Google Scholar
• QUAAS L, HOFFMANN B, ZAHRADNIK HP: Wechsel-wirkungen von Sexualsteroiden, Prostaglandinen (6-keto-PGF lalpha, PGF2alpha) und 13-adrenergen Agonisten (Adrenalin, Fenoterol-PartusistenR) im menschlichen nicht-schwangeren Myometrium in vi-tro. Z. Geburtsh. u. Perinat. (1986) 190:204–209.
   PubMedGoogle Scholar
• Important in vitro study for the understanding of the involvement of prostacyclin in the pharmacologic action of tocolytics.
   Google Scholar
• QUESADA JR, ALEXANIAN R, HAWKINS M, BARLOGIE B, BORDEN E, ITRI L, GUTTERMAN JU: Treatment of multi-
   Google Scholar
• S. SO Oa pie myeloma with recombinant alpha-interferon. Blood (1986) 67:275–278.
   PubMed Web of Science ®Google Scholar
• QUESADA JR, RIOS A, SWANSON D: Antitumor activity of recombinant-derived interferon-alpha in metastatic re-nal cell carcinoma. J. din. Oncol. (1985) 3:1522–1528.
   PubMed Web of Science ®Google Scholar
• RANGES GE, FIGARI IS, ESPEVIK T, PALLADINO MA: Inhi-bition of cytotoxic T cell development by transforming growth factor and reversal by recombinant tumor ne-crosis factor. J. Exp. Med. (1987) 166:991–998.
   PubMed Web of Science ®Google Scholar
• RAWLINSON L, DALTON BJ, ROGERS K, REES RC: The Influence of interferon, alfa and gamma, singly or in combination on human natural cell mediated cytotoxic-ity. Biosci. Rep. (1988) 9:549–556.
   Web of Science ®Google Scholar
• REDDY KB, MANGOLD GL, TANDON AK, YONEDA T, MUNDY GR, ZILBERSTEIN A, OSBORNE CK: Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res. (1992) 52:3636–3641.
   PubMed Web of Science ®Google Scholar
• REDMAN BG, FLAHERTY L, CHOU TH, AL-KATIB A, KRAUT M, MARTINO S, CHEN B, KAPLAN J, VALDIVIESO M: A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer. J C7in. Oncol. (1990) 8:1269–1276.
   Google Scholar
• REMAURY A, PARIS H: The insulin secreting cell line RINm5F expresses an alpha-2D adrenoceptor and nonadrenergic idazoxan binding sites. J. Pharmacol. Exp. Ther. (1992) 260:417–426.
   PubMed Web of Science ®Google Scholar
• RENDU F, ELDOR A, GRELAC F, BACHELOT C, GAZIT A, GILON C, LEVYTOLEDANO S, LEVITZKI A: Inhibition of platelet activation by tyrosine kinase inhibitors. Bio-chem. Pharmacol. (1992) 44:881–888.
   PubMed Web of Science ®Google Scholar
• RICE G, CHANEY R, WEST J, BURSTEN S, TOMPKINS C, SUNKARA P, SINGER JW: Inhibition of tumour cell adhe-sion to activated human umbilical vein endothelial cells (HUVEC) by novel compounds that inhibit phos-pholipid signaling. ProcAACR (1994) 35: 21. (Abstr.)
   Google Scholar
• RICE G, GALLIS B, SUNKARA P, SINGER JW, BURSTEN S: Inhibition of FGF, VEGF, and PDGF endothelial cell mitogenesis by inhibition of phosphatidic acid. Proc.AACR (1994) 35: 67. (Abstr.)
   Google Scholar
• RICE GC, BROWN PA, KAZLAUSKAS A, SINGER JW, BIANCO JA, BURSTEN SL: Generation of the lipid second messen-ger molecule phosphatic add is involved in signal transduction for PDGF, VEGF and EGF-induced mito-genesis. J.Cell Biochem (1994) 18A(Suppl.):272 (Abstr.).
   Google Scholar
• RICE GC, BROWN PA, NELSON R, BIANCO JA, SINGER JW, BURSTEN SE: Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. Proc.Natl.Acad.Sci.USA (1994) (in press):
   Google Scholar
• RICE GC, ROSEN JW, WEEKS R, MICHNICK J, BURSTEN SL, BIANCO JA, SINGER JW: CT-1501R selectively inhibits induced inflammatory monokines in human whole blood ex vivo. Shock (1994) 1: 1–13.
   PubMedGoogle Scholar
• RICE GC, TINO W, BURSTEN SL, VALENTINE M, BIANCO JA, SINGER JW: Development of novel specific pharma-cologic inhibitors of intereukin-2 (IL-2) signaltransduc-don. Blood (1993) 82: 189a.
   Web of Science ®Google Scholar
• RICHARDS JM, MICK R, LATTA J, DALY K, RATAIN M, VARDIMAN J, GOLOMB HJ: Serum soluble interleukin-2 receptor is associated with cllnienl and pathological disease status in hairy cell leukemia. Blood (1990) 76: 1941-1945.
   Google Scholar
• RICHARDS JM: Sequential chemoimmunotherapy for metastatic melanoma. Sem. Oncol. (1991) 18:91–95.
   PubMed Web of Science ®Google Scholar
• RIEDEL H, MASSOGLIA J, SCHLESSINGER J, ULLRICH A: Ligand activation of overexpressed epidermal growth factor receptors transforms NIH-3T3 mouse fibroblasts. Proc. Natl. Acad. (1988) 85:1477–1481.
   PubMed Web of Science ®Google Scholar
• RIVOLTINI L, ARIENTI F, BELLI F, GAMBOCORTI-PASSER-INI C, CASCINELLI N: In vitro preferential lysis of autolo-gous melanoma by tumor infiltrating lymphocytes (TH.). Association with clinical response after immu.no-therapy with TH. and IL–2.
   Google Scholar
• Proc. Amer. Soc. Cancer Res. (1992) 33:1943.
   Google Scholar
• ROBERTS JM: Current understanding of pharmacologic mechanisms in the prevention of pre-term birth. Clin. Obstet. Gynecol. (1984) 27:592–605.
   PubMed Web of Science ®Google Scholar
• ROBERTSON RP, HALTER JB, PORTE D: A role for alpha- adrenergic receptors in abnormal insulin Secretion in diabetes mellitus. J Clin. Invest. (1976) 57:791–795.
   PubMed Web of Science ®Google Scholar
• RODECK U, BECKER D, HERLYN M: Basic fibroblast growth factor in human melanoma. Cancer Cells (1991) 3:308–311.
   PubMed Web of Science ®Google Scholar
• RODECK U, HERLYN M, HERLYN D, MOLTHOFF C, ATKIN-SON B, VARELLO M, STEPLEWSKI Z, KOPROWSKI H: Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: Immunologi-cally mediated and effector cell-independent effects. Cancer Res. (1987) 47:3692–3696.
   PubMed Web of Science ®Google Scholar
• ROGEL JS, WEINBERG RA, FANNING P, KLAGSBRUN M: Basic fibroblast growth factor fused to a signal peptble transforms cells. Nature (1988) 331:173–175.
   PubMed Web of Science ®Google Scholar
• RONDEEL JMM, DE GREEF WJ, VAN HAASTEREN GAC, KLOOTWIJK W, VISSER TJ: Regulation of a TRH-like peptide in the anterior pituitary. J. Endocrinol. Invest. (1993) 6\(Suppl. 1): Abstr. C 51.
   Google Scholar
• RONNER P, CHEONG E, ICHALID P, TUMAN RW, MAT-SCHINSKY FM: Effect of linogliride on hormone release from perfused rat pancreas - fuel dependence and desensiti7Ation by tolbutamide. Dtabews (1991) 40:878–884.
   Google Scholar
• RONNER P, HANG TL, KRAEBBER MJ, HIGGINS TJ: Effect of the hypoglycaemic drug (-)-AZ-DF-265 on ATP-sensi-tive potassium channels in rat pancreatic O-cells. Br. J Pharmacol. (1992) 106:250–255.
   PubMed Web of Science ®Google Scholar
• Evidence for interaction of a non-sulphonylurea drug with the sulphonylurea receptor in the pancreatic B-cell.
   Google Scholar
• RONNER P, HIGGINS TJ, KIMMICH GA: Inhibition of ATP-sensitive le channels in pancreatic O-cells by non-suffonylurea drug linog,liride. Diabetes (1991) 40:885–892.
   PubMed Web of Science ®Google Scholar
• ROOK AH, KEHRL JH, WAKEFIELD AM, ROBERTS AB, SPORN MB, BURLINGTON BD, LANE CH, FAUCI AS: Effects of transforming growth factor 13 on the functions of natural killer cells: Depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol. (1986) 136:3916–3920.
   PubMed Web of Science ®Google Scholar
• ROSEN N, BOLEN JB, SCHWARTZ AM, COHEN P, DESEAU V, ISRAEL MA: Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J. Biol. Chem. (1986) 261:13754–13759.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE M, CHANG AE, AVIS FP, LEITMANN S, LINEHAN WM, ROBERTSON CN, LEE RE, RUBIN JT, SEWP CA, SIMPSON CG, WHITE DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl. J. Med. (1987) 316:889–897.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE M, MUUL L: Observation on the systemic administration of autologous lympholdne-ac-tivated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl. J. Med. (1985) 313:1485–1492.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MT, MULE JJ: New approaches to the inununotherapy of cancer using interleukin-2. Ann. Intern. Med. (1988) 108:853–864.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MT, YANG JC, AEBERSOLD PM, LINEHAN WM, SEIPP CA, WHITE DE:Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. (1989) 210:474–485,
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MT, YANG JC, TOPALIAN SL, CHANGE, SCHWARTZENTRUBER DJ, AEBERSOLD P, LEIT-MAN S, LINEHAM WM, SEIPPC, WHITE DE, STEINBERG SM: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.]. Natl. Cancer Institute (1993) 85:622–631.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MT, YANG YC, LINEHAN WM, SEIPP C, CALABRO S, KARP SE, SHERRY RM, STEINBERG S, WHITE DE: Combination therapy with interleukin-2 and alpha - interferon for the treatment of patients with advanced cancer.]. Clin. Oncol. (1989) 7:1863–1874.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, SCHWARZ SL, SPIESS PJ: Combination immunotherapy for cancer: Synergistic antitumor in-teractions of interleukin-2, alpha-interferon, and tu-mor-infiltrating lymphocytes. J. Natl. Cancer Institute (1988) 80:1393–1397.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA: The development of new itnmuno-therapies for the treatment of cancer using interleukin-2. Ann. Surg. (1985) 208:121–135.
   Google Scholar
• ROSS R: Platelet derived growth factor. Lancet (1989) 1:1179–1182.
   PubMed Web of Science ®Google Scholar
• RUBIN SC, FINSTAD CL, WONG GY, ALMADRONES L, PLANTE M, LLOYD KO: Prognostic significance of her-2/neu expression in advanced epithelial ovarian cancer - a multivariate analysis. Amer. J. Obstet. GynecoL (1993) 168:162–169.
   PubMed Web of Science ®Google Scholar
• RUSCETTI FW, MORGAN DA, GALLO RC: Functional and morphologic characterization of human T cells con-tinuously grown in vitro. J. Immunol. (1977) 119:131–140.
   PubMed Web of Science ®Google Scholar
• RUSSEL SM, KEEGAN AD, HARADA N, NAKAMURA Y, NOGUCHI M, LELAND P, ET AL.: Interleukin-2 receptor gamma-chain- a functional component of the Inter-leukin-4 receptor. Science (1993) 262:1880–1883.
   Google Scholar
• RYDEN G, ANDERSSON RGG, BERG G: Is the relaxing effect of betaadrenergic agonists on human myometrkun only transitory? Ada Obstet. Gynecol. Scan. (1982) 108(Suppl.):47–51.
   Google Scholar
• SAKAMOTO H, MORI M, TAIRS M, YOSHIDA T, MATSUK- AWA S, SHIMIZU K, SEIGGUCHI M, TERADA M, SUGIMURA T: Transforming gene from human stomach cancers and a noncancerous portion of stomach mucosa. Proc. Natl. Acad. Sci. USA (1986) 83:3997–4001.
   PubMed Web of Science ®Google Scholar
• SALING E, BRAND-NIEBELSCHÜTZ S, SCHMITZ C: Ver-meidung von Spitaborten und risikoreichen Priihge-burten - far die Routine geeignete Mal3nahmen. Z. Geburtsh. u. Pertnat. (1991) 195:209–221.
   PubMedGoogle Scholar
• System for the prevention and early detection of ascending genital infections adapted to the possibilities in ambulatory routine.
   Google Scholar
• SALING PM: How the egg regulates sperm function during gamete interaction: fact and fantasies. Biol. Re-prod. (1991) 44:246–251.
   PubMed Web of Science ®Google Scholar
• SANDGREN EP, LUETTEKE NC, PALMITER RD, BRINSTER RL, LEE DC: Overexpression of TGF-alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell (1990) 61:1121–1135.
   PubMed Web of Science ®Google Scholar
• SANTINI F, BEAVEN MA: Nonselective actions of her-bitnycin A. ImmunoL Today (1993) 14:369–370.
   PubMedGoogle Scholar
• SAPERSTEIN R, CHAPIN EW, BRADY EJ, SLATER EE: Effects of an az-adrenoceptor antagonist on glucose tolerance In the genetically obese mouse (C57BL/6J ob/ob). Meta-bolism (1990) 39:445–451.
   PubMed Web of Science ®Google Scholar
• SASADA R, KUROKAWA T, IWANE M, IGARASHI K: Trans-formation of mouse BALB/c 3T3 cells with human basic fibroblast growth factor cDNA. Mol. Cell. Biol. (1988) 8:588–594.
   PubMed Web of Science ®Google Scholar
• SAYA H, ARA S, LEE PSY, RO J, HUNG MC: Direct sequenc-ing analysis of transmembrane region of human lieu gene by polymerase chain reaction. Mol. Carinogen. (1990) 3:198–201.
   PubMed Web of Science ®Google Scholar
• SCHALL TS: Biology of the RANTES/SIS cytoldne family. Cytoktne (1991) 3: 165–183.
   PubMed Web of Science ®Google Scholar
• SCHENDEL DJ, ET AL.: Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lympho-cytes:modulation of recognition through retroviral transduction of tumor cells with interleukin-2 comple-mentary DNA and exogeneous alpha interferon treat-ment Cancer Res. (1993) 53:4020–4025.
   Google Scholar
• SCHLLL WB, HAIDL G: Medical treatment of male infer- tility. In: Infertility; Male and Female. (1993) Lunenfeld B, Insler V (Eds) Churchill Livingstone, Edinburgh pp 575–622. A comprehensive review of the current therapies used in the treatment of male infertility.
   Google Scholar
• SCHLESSINGER J, ULLRICH A: Growth factor signaling by receptor tyrosine kinases. Neuron (1992) 9:383–391.
   PubMed Web of Science ®Google Scholar
• SCHULZ A, HASSELBLATT A: Dual action of clonidine on Insulin release: suppression but stimulation when az-adrenoceptors are blocked. NS Archiv. Pharmacol (1989) 340:712–714.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ RS, HOLMES DR, TOPOL EJ: The restenosis paradigm revisited: An alternative proposal for cellular mechanisms./ Am, Coll. CardioL (1992) 20:1284–1293.
   PubMed Web of Science ®Google Scholar
• SCHWINN DA: Adrenoceptors as models for G protein-coupled receptors: structure, function and regulation. Br.]. Anaesthesia (1993) 77–85.
   Google Scholar
• An up to date review which integrates the pharmacology and molecular biology of cx2-adrenoceptors.
   Google Scholar
• SCOTT ML, VAN El 1EN RA, DALEY GQ, BALTIMORE D: V-abl causes hematopoietic disease distinct from that caused by bcr-abL Proc. Natl. Acad. Sci. USA (1991) 88 :6506–6510.
   PubMed Web of Science ®Google Scholar
• SEYMOUR L, DAJEE D, BEZWODA WR: Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast can-cer. Breast Cancer Res. Treat. (1993) 26:247–252.
   PubMed Web of Science ®Google Scholar
• SHALLOWAY D, SHENOY S: Oncoprotein kinases in mitosis. Adv. Cancer Res. (1991) 57:185–225.
   PubMed Web of Science ®Google Scholar
• SHAMAH SM, STILES CD, GUHA A: Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol. Cell Biol. (1993) 13:7203–7212.
   PubMed Web of Science ®Google Scholar
• SHEPARD HM, LEWIS GD, SARUP JC, FENDLY BM, MANEVAL D, MORDENTI J, FIGARI I, KOTTS CE, PALLAD-INO MA, ULLRICH A, SLAMON D: Monoclonal antibody therapy of human cancer - taking the ber2 proto-onco-gene to the clinic. J. Clin. Immunol. (1991) 11:117–127.
   PubMed Web of Science ®Google Scholar
• SHEWARD WJ, HARMAN AJ, FRASER HM, FINK G: Thy-rotropin-releasing hormone in rat pituitary stalk blood and hypothalamus: studies with high performance liq-uid chromatography. Endocrinol. (1983) 113:1865–1868.
   PubMed Web of Science ®Google Scholar
• SHI DR, HE GP, CAO SL, PAN WS, ZHANG HZ, YU DH, HUNG MC: Overexpression of the c-erbB-2/neu encoded p185 protein in primary lung cancer. Mol. Carcinogen. (1992) 5:213–218.
   PubMed Web of Science ®Google Scholar
• SHLRAISHI T, OWADA MK, TATSUKA M, FUSE Y, IUYOSHI W, KAICUNAGA T: A tyrosine-specific protein kinase inhibitor, acyno-3ethoxy-4hydroxy-5-phenylthio-rnethylcinnamamide, blocks the phosphorylation of tyrosine kinase substrate in intact cells. Jpn. J. Cancer Res. (1990) 81:645–652.
   PubMedGoogle Scholar
• SHIRAISHI T, OWADA MK, TATSUKE M, YAMASHITA T, WATANABE K, KAKUNAGA T: Specific inhibitors of tyro-sine-specific protein kin•ses: properties of 4-hydroxy-cinnarnatri4df- derivatives in vitro. Cancer Res. (1989) 49:2374–2378.
   PubMed Web of Science ®Google Scholar
• SHUKLA SD: Inositol phospholipid turnover in PAF transmembrane signalling. Lipids (1991) 26: 1028–1033.
   PubMed Web of Science ®Google Scholar
• SILAGI S, DUTKOWSKI R, SCHAEFER A: Eradication of mouse melanoma by combined treatment with recom-binant human interleukin- 2 and recombinant murine interferon-gamma. Internatl. J. Cancer (1988) 41:315–322.
   PubMed Web of Science ®Google Scholar
• SILVER BJ: Platelet-derived growth factor in human malignancy. Biofactors (1992) 3:217–227.
   PubMed Web of Science ®Google Scholar
• SLEIJER DT, JANSSEN RAJ, SUTER J, DE VRIES EGE, WILLEMSE PHB, MULDER NH: Phase II study of subcuta-neous interleukin-2 in unselected patients with ad-vanced renal cell cardnoma on an outpatient basis. J. Clin. Oncol. (1992) 10:1119–1123.
   PubMed Web of Science ®Google Scholar
• SMITH K, FENNELLY JA, NEAL DE, HALL RR, HARRIS AL: Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial blad-der tumors. Cancer Res. (1989) 49:5810–5815.
   PubMed Web of Science ®Google Scholar
• Smith KA: Interieukin-2: Inception, impact, and impli-cations. Science (1988) 240:1169–1182.
   PubMed Web of Science ®Google Scholar
• SMYTH MS, STEFANOVA I, HARTMANN F, HORAK ID, OSHEROV N, LEVITZKI A, BURKE TR: Non-amine based analogues of lavendustin-A as protein-tyrosine kinase inhibitors. J. Med. Chem. (1993) 36:3010–3014.
   PubMed Web of Science ®Google Scholar
• SMYTH MS, STEFANOVA I, HORAK ID, BURKE TR: Hy-droxylated 2- (5'-salicypnaphthalenes as protein-tyro-sine kinase inhibitors. J. Med. Chem. (1993) 36:3015–3020.
   PubMed Web of Science ®Google Scholar
• SONE S, UTSUGI T, NII A, OGURA T: Differential effects of recombinant interferons alpha, beta, gamma on induction of human lymphokine-activated killer activ-ity. J. Natl. Cancer Institute (1988) 80:425–431.
   PubMed Web of Science ®Google Scholar
• SOSMAN JA, KOHLER PC, HANK JA, SONDEL PM: Repeti-tive weekly cycles of interleukin-2. Clinical and immu- nologic effects of dose, schedule, and addition of in-domethacin. J. Natl. Cancer Institute (1988) 80:14514461.
   Google Scholar
• SPARANO JA, MICETICH KC, SUNDERLAND M, MARGOLIN K, ARONSON F, SZNOL M, RUBINSTEIN LV: A randomized phase Ill trial of treatment with high-dose interleukin-2 either alone or in combination with interferon-2 alpha in patients with advanced melanoma. Proc. Amer. Soc. Clin. Oncol. (1993) 12:1332.
   Google Scholar
• SPÄTLING L, FALLENSTEIN F, SCHNEIDER H, DANCIS J: Bolus tocolysis: Treatment of preterm labour with pul-satile administration of a beta-adrenergic agonist Am. Obstet. Gynecol. (1989) 160:713–717.
   Web of Science ®Google Scholar
• New concept for administration of tocolytics considering uterine contraction physiology and release charasteristics of adrenergic substances.
   Google Scholar
• SPITS H, YSSEL H, PALIARD X, KASTELEIN R, FIGDOR C, DEVRIES JE: 11-4 inhibits IL-2 mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes In mixed leukocyte cultures. J. Immunol. (1988) 141:29–36.
   PubMed Web of Science ®Google Scholar
• SPITS H, YSSEL H, TAKEBE Y, ARM N, YOKOTA T, LEE F, ARM KI, BANCHERAEU J, DEVRIES JE: Recombinant in-terleukin-4 promotes the growth of human T cells. J. Immunol. (1987) 139:1142–1147.
   PubMed Web of Science ®Google Scholar
• SPLAWSKI JB, JELINEK DF, LIPSKY PE: Immunomudula-tory role of IL-4 on the secretion of Ig by human B cells. J. Immunol. (1986) 142:1569–1575.
   Google Scholar
• SPORN MB, ROBERT AS, WAKEFIELD AM, ASSOIAN RK: Transforming growth factor [I: biological function and chemical structure. Science (1986) 233:532–534.
   PubMed Web of Science ®Google Scholar
• STANCOVSKI I, HURWITZ E, LEINER O, ULLRICH A, YARDEN Y, SELA M: Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tu.mor growth. Proc. Natl. Acad. Sc!. USA (1991) 88: 8691–8695.
   PubMed Web of Science ®Google Scholar
• STEELE R: Epidermal growth factor receptor expression in colorectal cancer. British Surg. (1990) 77:1352–1354.
   PubMed Web of Science ®Google Scholar
• STEIN RC, MALKOVSKA V, MORGAN S, GALAZKA A, AN-ISZEWSKI C, ROY SE, SHEARER RJ, MARSDEN RA, BEVAN D, GORDON-SMITH EC, COOMBES RC: The clinical effects of prolonged treatment of patients with advanced can-cer with low-dose subcutaneous interleukin 2. Br. J Cancer (1991) 63:275–279.
   PubMed Web of Science ®Google Scholar
• STEIS RG, URBA WJ, VANDERMOLEN LA, ET AL.: Intraperi- toneal lymphokine-activated killer cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J. Clin. Oncol. (1990) 8:1618–1629.
   Google Scholar
• STERN DF, HARE DL, CECCHINI MA, WEINBERG RA: Con-struction of a novel oncogene based on synthetic se-quences encoding epidermal growth factor. Science (1987) 235:321–324.
   PubMed Web of Science ®Google Scholar
• STERNBERG MJE: Neu receptor dimerization. Nature (1989) 339:587.
   PubMed Web of Science ®Google Scholar
• STÔTTER H, WIEBKE E, TOMITA S, BELLDEGRUN A, TOPALIAN S, ROSENBERG SA, LOTZE M: Cytokines alter target cell susceptibility to lysis. j Immunol. (1989) 142:1767–1773.
   PubMed Web of Science ®Google Scholar
• STRIGL R, PFEIFFER U, ERHARDT W, BLÜMEL G: Bietet der Kalziumantagonist Verapamil bei der Tokolyse mit Beta-Sympathikomimetika den erwarteten Schutz vores Myokardschaden. Geburtsh. u. Frauenheilk. (1980) 40:500–506.
   Google Scholar
• This paper was essential for the disproval of useless comedications with verapamil, meant to act as cardioprotection.
   Google Scholar
• STRUTHERS AD, BROWN DC, BROWN MJ, SCHUMER B, BLOOM SR: Selective a2-receptor blockade facilitates the Insulin response to adrenaline but not to glucose in man- Clin. Endocrinol. (1985) 23:539–546.
   Web of Science ®Google Scholar
• SUDA Y, AIZAWA S, FURUTA Y, YAGI T, LKAWA Y, SAITOH K, YAMADA Y, TOYOSHIMA K, AND YAMAMOTO T: Induction of a variety of tumors by c-erbB2 and clonal nature of lymphomas even with the mutated gene (Va1659----61u659). EMBOJ. (1990) 9:203–212.
   Google Scholar
• SUNKARA PS, FINNEY R, STRINGER C, UNDEREINER G, RICE G, BURSTEN S, BIANCO JA, SINGER JW: A novel class of low molecular weight phospholipid signaling inhibi-tors are selectively cytotoxic for tumor cells. Proc.AACR (1994) 35: 409. (Abstr.)
   Google Scholar
• SUZUKAKE-TSUCHIYA K, MORIYA Y, HORI M, UEHARA Y, TAKEUCHI T: Induction by herbinrycin A of contact Inhibition in v-src- expressed cells. J. Antibiot (1989) 42:1831–1837.
   PubMed Web of Science ®Google Scholar
• SUZUKI R, SUZUKI S, EBINA N, KUMAGAI K: Suppression of alloitrunune cytotoxic T lymphocyte (CTL) genera-tion by depletion of NK cells and restoration by inter-feron and/or interleukin-2. J. Immunol. (1985) 134:2139–2148.
   PubMed Web of Science ®Google Scholar
• SVEDERSKY LP, NEDWIN GE, GOEDDEL DV, PALLADINO MA: Interferon-gamma enhances induction of lympho-toxin in recombinant interleukin-2 stimulated periph-eral blood mononuclear cells. J. Immunol. (1985) 134:1604–1608.
   PubMed Web of Science ®Google Scholar
• SVEDERSKY LP, SHEPARD HM, SPENCER SA, SHALABY MR, PALLADINO MA: Augmentation of human natural cell-mediated cytotoxicity by recombinant human inter-leukin-2. j Immunol. (1984) 133:714–718.
   PubMed Web of Science ®Google Scholar
• SZCZYLIK C, SKORSKI T, NICOLAIDES NC, MANZELLA L, MALAGUARNERA L, VENTTURELLI D, GEWIRTZ AM, CALABRETTA B: Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynu-cleotides. Science (1991) 253:562–565.
   PubMed Web of Science ®Google Scholar
• Supports the concept that inactivating the BCR-ABL oncogene will selectively kill leukaemia cells harbouring this gene.
   Google Scholar
• SZNOL M, JANIK JE, SHARFMAN WH, STEIS RG, SMITH JW, URBA WJ, FENTON RG, CREEKMORE SP, FREY G, LONGO DL: A phase Ia/Ib study of subcutaneously administered iaterleukin-2 in combinantion with interferon-alpha 2a. Proc. Amer. Assoc. Clin. Oncol. (1991) 10:209.
   Google Scholar
• TAGLIABUE E, CENTIS F, CAMPIGLIO M, MASTROIANNI A, MARTIGNONE S, PELLEGRINI R, CASALINI P, LANZI C, MENARD S, COLNAGHI MI: Selection of monoclonal antibodies which induce internalization and phospho-rylation of p185ber2 and growth inhibition of cells with ber2/neu gene amplification. Internat. J. Cancer (1991) 47:933–937.
   PubMed Web of Science ®Google Scholar
• TALAMONT1 MS, ROH MS, CURLEY SA, GALLICK GE: In-crease in activity and level of pp60c-src in progressive stages of human colorectal cancer. J. Clin. Invest. (1993) 91:53-60- High correlation between the activity of pp60"rc and progression of colon cancer.
   Google Scholar
• TALEGHANI BM, POROWSKI P, KLINK M, GUNZER U:In-terleukin-2 and alpha-interferon sc in combination with 5-fluorouracil and folinic acid iv in advanced progressive colorectal can. Ann. Hematol. (1991) 6:126.
   Google Scholar
• TALPAZ M, KANTARJIAN HM, MCCREEDIE K: Hematologic remission and cytogenic improvement induced by re-combinant human interferon- alpha 2A in chronic myelogenous leukemia. N. Engl. J. Med. (1986) 314:1065–1069.
   PubMed Web of Science ®Google Scholar
• TAMURA T, SASAKI Y, SHINKAI T, EGUCHI K, SAKURAI M, FUJIWARA Y, NAKAGAWA K, MINATO K, BUNGO M, SAIJO N: Phase I study of combination therapy with inter-leukin-2 and 8-interferon in patients with advanced malignancy. Cancer Res. (1989) 49:730–735.
   PubMed Web of Science ®Google Scholar
• TANIGUCHI M, UEHARA Y, MATSUYAMA M, TAKAHASHI M: Inhibition of ret tyrosine kinase activity by herbimy-cin-A. Biochem. Biophys. Res. Comm. (1993) 195:208–214.
   PubMed Web of Science ®Google Scholar
• TATEISHI M, ISH1DA T, MITSUDOMI T, KANEKO S, SUGI-MACHI K: Prognostic value of c-erbB-2 protein expres-sion in human lung adenocarcinoma and squamous cell cardnoma. Eur. J. Cancer (1991) 27:1372–1375.
   PubMed Web of Science ®Google Scholar
• TAYLOR WR, GREENBERG AH, TURLEY EA, WRIGHT JA: Cell motility, invasion, and malignancy induced by overexpression of k-FGF or bFGF. Exper. Cell Res. (1993) 204: 295–301.
   PubMed Web of Science ®Google Scholar
• THETLET C, LE ROY X, DE LAPEYRIERE O, GROSGEORGES J, ADNANE J, RAYNAUD SD, SIMONY-LAFONTAINE J, GOLDFARB M, ESCOT C, BIRNBAUM D, GAUDRAY P: Amplification of FGF-rrelated genes in human tumors: possible involvement of HST in breast cardnomas. Oncogene (1989) 4:915–922.
   PubMed Web of Science ®Google Scholar
• THETFORD CR, MORRELL JM, COCKLE SM: TRH-related peptides in rabbit prostate complex during develop-ment. Biochim. Biophys. Acta (1992) 1115:252–258.
   PubMed Web of Science ®Google Scholar
• THIERY M, AMY JJ: Inhibition of labour. In: Prostaglandins, and their inhibitors in clinical obstetrics and gynecology. Bygdeman M, Berger GS, Keith LG (Eds), MTP Press Ltd., Lancaster, 1986, p203–231.
   Google Scholar
• THOMPSON AM, REWCASTLE GW, TERCEL M, DOBRUSIN EM, FRY DW, KRAKER AJ, DENNY WA: Tyrosine kinase inhibitors. 1. Structure- activity relationships for inhi-bition of epidermal growth factor receptor tyrosine kinase activity by 2,3-dihyro-2thioxo-1H- indole-3-al-kanoicacids and 2,2'-dithiobis(H-indole-3-alkanoic ac-ids). J. Med. Chem. (1993) 36:2459–2469.
   Google Scholar
• THOMPSON AM„ FRY DW, KRAKER AJ, DENNY WA: Tyro-sine kinase inhibitors. 2. Synthesis of 2,2'-dithlobis(1H-indole-3-alkanoic adds and 2,2'-dithiobis (1H-indole-3-alkanoic adds). J. Med. Chem. (1994) 37:598–609.
   Google Scholar
• THOMPSON JA, LEE DJ, LINDGREN CG, BENZ LA, COLLINS C, LEVITT D, FEFER A: Influence of dose and duration of interleukin-2 on toxidty and immunomodulation. J. Clin. Oncol. (1988) 6:669–678.
   PubMed Web of Science ®Google Scholar
• THOMPSON TA, ANDERSON kD, DIPIETRO TM, ZWIEBEL TA, ZAME IiL M, ANDERSON WF, MACIAG T: Site-directedneovessel formation in vivo. Science (1988) 241:1349–1352.
   PubMed Web of Science ®Google Scholar
• TOI M, NAKAMURA T, MUKAIDA H, WADA T, OSAKI A, YAMADA H, TOGE T, NLIMOTO M, HATTORI T: Relation-ship between epidermal growth factor receptor status and various prognostic factors in human breast cancer. Cancer (1990) 65:1980–1984.
   PubMed Web of Science ®Google Scholar
• TOI M, OSAICI A, YAMADA H, TOGE T: Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur. J. Cancer (1991) 27:977–980.
   PubMed Web of Science ®Google Scholar
• TOKUDA Y, EBINA N, GOLUB SH: The inhibitory effect of human interferon alpha on the generation of lym-phokine-activated killer activity. Cancer Immunology and Immunotherapy (1959) 30:205–212.
   Google Scholar
• TOLEDANO M, MATHIOT C, MICHON J, ANDREU G, LANDO D, BRANDELY M, FRIDMAN WH: interferon-gamma and interleukin-2 in the generation of lymphok-ine-activated killer cell cytotoxicity. Cancer Immunol. Immunoth. (1989) 30:57–62.
   PubMed Web of Science ®Google Scholar
• TOTH, PD: The biological effects of PAF antagonists on endotoxernia. In: Platelet Activating Factor in Endotoxin and Immune Diseases, New York: Dekker, Inc., 1990, p589–608.
   Google Scholar
• TRACEY KJ, FONG Y, HESSE DG, MANOGUE KR, LEE AT, KUO GC, LOWRY SF, CERAMI A: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (1987) 330: 662–664.
   PubMed Web of Science ®Google Scholar
• TRAXLER P, BUCHDUNGER E, METT H, MEYER T, RE-GENASS U, ROESEL J, TRINKS U, LYDON N: Aminoalkyl-acrylophenones - selective inhibitors of EGF-R protein tyrosine kinase. Proc . Am. Assoc. Cancer Res . (1992) 33:527.
   Google Scholar
• TRAXLER PM, WACKER O, BACH HL, GEISSLER JF, KUMP W, MEYER T, REGENASS U, ROESEL JL, LYDON N: Sulfonyl-benzoyl-nitrostyrenes: Potential bisubstrate type in-hibitors of the EGF-receptor tyrosine protein kinase. J. Med. Chem. (1991) 34:2328–2337.
   PubMed Web of Science ®Google Scholar
• TRUITT GA, STERN U, BONTEMPO J: Recombinant hu-man interleukin-2, alone and in combination with Interferon-alpha, is a potent antitumor agent against colon 38 and Lewis lung carcinomas in mice. Proc. Amer. Assoc. Cancer Res. (1987) 28:369.
   Web of Science ®Google Scholar
• TSUKITA S, OISHI K, AK1YAMA T, YAMANASHI Y, YAMAMOTO T, TSUKITA S: Specific proto-oncogenic tyrosine kinases of src family are enriched in cell-to-cell adherens junctions where the level of tyrosine phos-phorylation is elevated. J. Cell Biol. (1991) 113:867–879.
   PubMed Web of Science ®Google Scholar
• TUTMAN RW, MORRIS DM, BRYAN DJ, WALLACE NH, VOINA SJ, BOWDEN CR, TUTWILER GF: Comparative effects of linogliride fumarate and tolbutamide sodium on insulin secretion and glucose utilization in rat pan-creatic islets. Drug Develop. Res. (1991) 24:355–363.
   Web of Science ®Google Scholar
• TYSON FL, BOYER CM, KAUFMAN R, OBRIANT K, CRAM G, CREWS JR, SOPER JT, DALY L, FOWLER WC, HASKILL JS, BAST RC: Expression and amplification of the her-2/Iseu (c-erbB-2) proto-oncogene in epithelial ovarian tumors and cell lines. Amer.J Obstet. Gynecol. (1991) 165:640–646.
   PubMed Web of Science ®Google Scholar
• UCHINO S, TSUDA H, MARUYAMA K, KINOSHITA T, SASAKO M, SATTO T, KOBAYASHI M, 111110HASHI S: Over-expression of c-erbB-2 protein in gastric cancer - its correlation with long-term survival of patients. Cancer (1993) 72:3179–3184.
   PubMed Web of Science ®Google Scholar
• UEHARA Y, FUKAZAWA H, MURAKAMI Y, MIZUNO 5: Irreversible inhibition of v-src tyrosine kinase activity by herbimrycin A and its abrogation by sulfhydryl com-pounds. Biochem. Biophys. Res. Commun. (1989) 163:803–809.
   PubMed Web of Science ®Google Scholar
• UEHARA Y, MURAKAMI Y, SUGIMOTO Y, MIZUNO S: Mechanism of reversion of Rous sarcoma virus trans-formation by herbbnycin reduction of total phospho- tyrosine levels due to reduced kinase activity and Increased turnover of p60v-srcl. Cancer Res. (1989) 49:780–785.
   PubMed Web of Science ®Google Scholar
• ULLRICH A, SCHIFSSINGER J: Signal transduction by receptors with tyrosine kinase activity. Cell (1990) 61:203–212.
   PubMed Web of Science ®Google Scholar
• ULMSTEN U, ANDERSSON RE, WINGERUP L: Treatment of premature labour with the calcium antagonist nifedip-ine. Arch. Gynecol. (1980) 229:1–5.
   PubMedGoogle Scholar
• Important clinical study about the clinical use of calcium channel blockers.
   Google Scholar
• ULMSTEN U: Treatment of normotensive and hyperten-sive patients with preterm labour using oral nifedipine, a calcium antagonist. Arch. Gynecol. (1984) 236:69–72.
   PubMedGoogle Scholar
• URANO K, ET AL.: Potentiation of therapeutic effect of recombinant tumor necrosis factor against B16 mouse melanoma by combination with 1L-2. Cytokine (1993) 5:224–229.
   Google Scholar
• VAAGE J: Pert-tumor interleukin-2 causes systemic therapeutic effect via interferon-gamma induction. In-ternatl. J. Cancer (1991) 49:598–600.
   PubMed Web of Science ®Google Scholar
• VAGLINI M, AMMATUNA M, ARIENTI F, PARMIANI G, PRADA A, SAN'TINAMI M, SANTORO N, BELLI F: Treatment of in transit metastases from cutaneous melanoma by isolation perfusion in extra-corporeal circulation with interleukin-2 and lymphokine-activated killer cells. Proc. Am. Soc. Chn. Oncol. (1993) 13:1324.
   Google Scholar
• VANDEGRIEND RJ, RONTELTAP CPM, GRAVEKAMP C, MONNIKENDAMM D, BOLHUIS RLH: EFN-fl and recombi-nant interleukin-2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3-negative natural killer cell-derived clones rather thean that of T3-positive clones. J. Immunol. (1986) 136:1700–1707.
   PubMed Web of Science ®Google Scholar
• VANETTEN RA: Malignant transformation by abl and bcr/abL In: Oncogenes and Tumor Suppressor Genes in Human Malignancies. Benz CC, Liu ET (Eds), Kluwer Aca-demic Publishers, Boston 1993 pp. 167–192.
   Google Scholar
• VASSAR R, FUCHS E: Transgenic mice provide new Insights into the role of TGFot during epidermal devel-opment and differentiation. Gene Des. (1991) 5:714–727.
   PubMed Web of Science ®Google Scholar
• VEILLE JC, BISSONNFITE JM, HOHIMER AR: The effect of a calcium channel blocker (nifedipine) on uterine blood flow in the pregnant goat. Am. J. Obstet. Gynecol. (1986) 1160–1163.
   PubMed Web of Science ®Google Scholar
• Important experimental study for the understanding of possible foetal side effects of calcium channel blockers.
   Google Scholar
• VELU TJ, BEGUINOT L, VASS WC, WILLINGHAM MC, MER- LINO GT, PASTAN I, LOWY DR: Epidermal growth factor-dependent transformation by a human EGF receptor proto-oncogene. Science (1987) 238:1408–1410.
   PubMed Web of Science ®Google Scholar
• VON WUSSOW P, FREUND M, BLOCK B, DIEDRICH H, POLIWODA H, DEICHER H: Clinical significance of anti-IFN-alpha antibody titres during interferon therapy. The Lancet (1987) 2:635–636.
   PubMed Web of Science ®Google Scholar
• WAHL SM, HUNT DA, WONG HL, DOUGHERTY S, MCCARTNEY F, WAHL LM, ELLINGSWORTH L, SCHMIDT JA, GALL G, ROBERTS AB, SPORN MB: Transforming growth factor j3 is a potent immunosuppressive agent that inhibits IL-1 dependent lymphocyte proliferation. J. Immunol. (1988) 40:3026–3032.
   Google Scholar
• WAKABAYASHI G, GELFAND JA, BURKE JF, THOMPSON RC, DINARELLO CA: A specific receptor antagonist for interleukin 1 prevents Escherichia coil-induced shock In rabbits. FASEB J. (1991) 5: 338–343.
   PubMed Web of Science ®Google Scholar
• WALDMANN T: The IL-2/11-2- receptor system: a target for rational immune intervention. Irnmunol. Today (1993) 14:264–270.
   PubMedGoogle Scholar
• WALEWSKI J, PAIETTA E, DUTCHER J, WIERNIK PH: Evalu-ation of natural killer and lympholdne-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autolo-gous LAK cells. J. Cancer Res. Clin. Oncol. (1989) 115:170–174.
   PubMed Web of Science ®Google Scholar
• WALKER RE, VARLEY JM: The molecular pathology of human breast cancer. Cancer Surv. (1993) 16:31–57.
   PubMedGoogle Scholar
• WAN YJ, ORRISON BM, LIEBERMAN R,: Induction of major histocompatibility class I antigens by interferons in undifferentiated F9 cals./. Cell Physiol. (1987) 130:76–283.
   Google Scholar
• WANG BC, KENNAN WS, YASUKAWA-BARNES J, LIND-STROM MJ, GOULD MN: Frequent induction of mammary • carcinomas following neu oncogene transfer into in situ mammary epithelial cells of susceptible and resis-tant rat strains. Cancer Research (October 15, 1991) 51: 5649–5654.
   Google Scholar
• WANG H, SMITH K: The interleukin-2 receptors. J. Exp. Med. (1987) 166:1055–1069.
   PubMed Web of Science ®Google Scholar
• WARD CR, STOREY BT: Determination of the time course of capacitation in mouse spermatozoa using a chlortet-racycline fluorescence assay. Devel. Biol. (1984) 104:287–296.
   PubMed Web of Science ®Google Scholar
• This investigation validates the use of the CTC assay for following capacitation in mouse epididymal sperm.
   Google Scholar
• WATANABE T, KUME T, TSUNEIZUMI K, KONDO K, SHI- RAISHI T, OISHI M: Synergistic induction of erythroid differentiation of mouse erythroleukemia cells by in-hibitors of topoisomerases and protein tyrosine ki-nases. Exp. Cell Res. (1992) 199:269–274.
   PubMed Web of Science ®Google Scholar
• WATERFIELD MD, SCREACE GT, WHITTLE N, STROOBANT P, JOHNSSON A, WASTESON A, WESTERMARK B, HELDIN C, HUANG JS, DEUEL TF: Platelet-derived growth factor Is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature (1983) 304:35–39.
   PubMed Web of Science ®Google Scholar
• WATKINS LF, LEVINE AE: Differential role of transform-ing growth factor-alpha in two human colon-carcinoma cell lines. Int.J. Cancer (1991) 47:455–460.
   PubMed Web of Science ®Google Scholar
• WEIDINGER H, PASSLOER HJ, KOVACS L, BERLE P: Nutzen der prophyLaktischen Vaginalantiseptik mit Hexetidin In Geburtshilfe wad Gynakologie. Geburts. u. Frauen-heilk. (1991) 51:929–935.
   PubMedGoogle Scholar
• Synopsis of the bacteriocidaVbacteriostatic properties of a new vaginal antiseptic.
   Google Scholar
• WEINER LM, PADAVIC-SHALLER K, KTTSON J, WATTS P, KRIGEL RL, LITWIN S: Phase I evaluation of combinant therapy with interleukin-2 and gamma-interferon. Can-cer Res. (1991) 51:3910–3918.
   PubMed Web of Science ®Google Scholar
• WEISS GR, MARGOLIN KA, ARONSON FR, SZNOL M, AT-KINS MB, DUTCHER JP: A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J. Clin. Oncol. (1992) 10: 275–281.
   PubMed Web of Science ®Google Scholar
• WEN DZ, PELES E, CUPPLES R, SUGGS SV, BACUS SS, LUO Y, TRAIL G, HU S, SILBIGER SM, BENLEVY R, KOSKI RA, LU HS, YARDEN A': Neu differentiation factor - A transmem-brane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell (1992) 69:559–572.
   PubMed Web of Science ®Google Scholar
• WEST WH, TAUER KW, YANNELLI JR, MARSHALL GD, ORR DW, THURMAN GB, OLDHAM RK: Constant infusion recombinant interleukin-2 in adoptive immu.notherapy of advanced cancer. N. Engl. J. Med. (1987) 316:898–905.
   PubMed Web of Science ®Google Scholar
• West WH: Clinical application of continuous infusion of recombinant interleukin-2. Eur. J. Cancer Clin. Oncol. (1989) 25:11–15.
   Google Scholar
• WESTERMARK B, SIEGBAHN A, HELDIN CH, CLAESSON-WISH L: B- type receptor for platelet-derived growth factor mediates a chemotactic response by means of ligand-induced activation of the receptor protein-tyro-sine kinase. Proc. Natl. Acad. Sci. USA (1990) 87:128–132.
   PubMed Web of Science ®Google Scholar
• WESTERMARK B: PDGF and its receptors in human tumor cells In: Biology of Platelet - Derived Growth Factor. Cytokines. Westermark B, Sorg C (Eds) Basel, Karger 1993 5:146–162.
   Google Scholar
• WHITESELL L, SHIFRIN SD, SCHWAB G, NEC10ERS LM: Benzoquinonoid ansamrycins possess selective tumori-cidal activity unrelated to src kinase inhibition. Cancer Res. (1992) 52:1721–1728.
   PubMed Web of Science ®Google Scholar
• WIDMER MB, ACRES BR, SASSENFELD HM, GRABSTEIN ICH: Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor-1 (inter-leukin-4). Exp. Med. (1987) 166:1447–1455.
   PubMed Web of Science ®Google Scholar
• WIEBKE E, ROSENBERG SA, LOTZE M: Acute immunologic effects of interleukin-2 therapy in cancer patients. J. Clin. Oncol. (1988) 6:1440–1449.
   PubMed Web of Science ®Google Scholar
• WINKELHAKE JI, STAMPFL S, ZIMMERMAN RJ: Synergistic effects of combination therapy with human recombi-nant interleukin-2 and tumor necrosis factor-alpha against primary lung cancer targets. Cancer Immunol. Immunoth. (1989) 29:193–108.
   PubMed Web of Science ®Google Scholar
• WIQVIST N: The use of inhibitors of prostaglandin synthesis in obstetrics. In: Human Parturition. Keirse MJNC, Anderson ABM, Bennebroek Gravenhorst J (Eds), Martinus Nijhoff, The Hague, 1979, p189–200.
   Google Scholar
• WISCHNIK A, HERM:ER M, ALBERTI W: Clenbuterol als neues Tokolytikum zur oralen Anwendung - Klinische Ergebnisse. In: Neueste Dgebnisse ilber Betarnimetika Jung H, Fendel H, Karl C (Eds) Steinkopff Verlag Darmstadt, 1986, p88–99.
   Google Scholar
• WISCHNIK A, HOTZINGER H, SCHROLL A, TRENKWALDER U, WISCHNIK B, HE1MISCH W, WEIDENBACH A: Clen-buterol und Fenoterol - Tierexperimenteller Verglekh zweier Tokolytika. Z. Geburtsh. u. Perinat (1984) 188:228–233.
   PubMedGoogle Scholar
• WISCHNIK A: Risk-benefit assessment of tocolytic drugs. Drug Safety (1991) 6(5):371–380.
   PubMed Web of Science ®Google Scholar
• Survey about current therapeutical procedures, critical consideration of indications in view of modem neonatologic concepts WOOD DP, WARTINGER DD, REUTER V, CORDONCARDO C, FAIR WR, CHAGANTI RSK: DNA, RNA and inununohis-tochemical characterization of the HER2/neu oncogene In transitional cell carcinoma of the bladder. J. Urol. (1991) 146:1398–1401.
   PubMed Web of Science ®Google Scholar
• WORKMAN P: Signal transduction inhibitors as novel anticancer drugs: Where are we? Ann. Oncol. (1992) 3:527–531.
   Google Scholar
• WYKE AW, CUSHLEY W, WYICE JA: Mitogenesis by v-str: A need for active oncoprotein both in leaving GO and in completing G1 phases of the cell cycle. Cell Growth Differ. (1993) 4:671–678.
   PubMedGoogle Scholar
• YAMAMOTO T, KAMATA N, KAWANO H, SHIMIZU S, ICUROKI T, TOYOSHIMA K, RIKIMARU K, NOMURA N, ISHIZAICI R, PASTAN I: High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines. Cancer Res. (1986) 46:414–416.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI H, FUKUI Y, UEYAMA Y, TAMAOKI N, KAWAMOTO T, TANIGUCHI S, SH1BUYA M: Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c- erbB) in human brain tumors. Mol. Cell. Blot (1988) 8:1816–1820.
   PubMed Web of Science ®Google Scholar
• YANG SC, GRIMM EA, PARKINSON DR, CARINHAS J, FRY KD, MENDIGUREN-RODRIGUEZ A, LICCIARDELLO J, OWEN-SCHAUB LB, HONG WK, ROTH JA: Clinical and immunomodulatory effects of combinant immuno-therapy with low-dose interleukin-2 and tumor ne-crosis factor-alpha in patients with advanced non-small cell lung cancer: A phase I trial. Cancer Res. (1991) 51:3669–3676.
   PubMedGoogle Scholar
• YANG SC, OWEN-SCHAUB LB, GRIMM EA, ROTH JA: In-duction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-alpha against primary lung cancer targets. Cancer. Immunol. Immunoth. (1989) 29:193–108.
   PubMed Web of Science ®Google Scholar
• YARDEN Y, PELES E: Biochemical analysis of the ligand for the neu oncogenic receptor. Biochemistry (1991) 30:3543–3550.
   PubMed Web of Science ®Google Scholar
• YARDEN Y: Agonistic antibodies stimulate the kinase encoded by the neu proto-oncogene in living cells but the oncogenic mutant is constitutively active. Proc. Natl. Acad. Sci. USA (1990) 87:2569–2573.
   PubMed Web of Science ®Google Scholar
• YASUI W, HATA J, YOKOZAKI H, NAKATANI H, OCHIAI A, ITO H, TAHARA E: Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma. Int. J. Cancer (1988) 41:211–217.
   PubMed Web of Science ®Google Scholar
• YONEDA, T, LYALL RM, ALSINA MM, PERSONS PE, SPADA AP, LEVITZKI A, ZILBERSTEIN A, MUNDY G. R.: The anitproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squarnous cell carcinoma in vitro and in nude mice. Cancer Res. (1991) 51:4430–4435.
   Google Scholar
• One of the few reports demonstrating in vivo antitumor activity with a tyrosine kinase inhibitor.
   Google Scholar
• YOSHIDA T, HIROAKA N, YOSHIOKA K, HASEGAWA G, KONDO M: Anti-obesity and anti-diabetic actions of 133-adrenoceptor agonist BRL 26830A in yellow KK mice. Endocrinol. Japon (1991) 38:397–403.
   PubMedGoogle Scholar
• YOSHIDA T: The anti-diabetic O3-adrenoceptor agonist BRL 26830A works by release of endogenous insulin. Am. J. Clin. Nutr. (1992) 55:237S–241S.
   Google Scholar
• YOUNG P, BERGE J, CHAPMAN H, CAWTHORNE MA: Novel a2-adrenoceptor antagonists show selectivity for a2A- and aukadrenoceptor subtypes. Eur. j Pharmacol. (1989) 168:381–386.
   PubMed Web of Science ®Google Scholar
• First evidence for the development of antagonists that can differen-tiate between ocradrenoceptor subtypes.
   Google Scholar
• YOUNGBLOOD WW, LIPTON MA, KIZER JS: TRH-like immunoreactivity in urine, serum and extrahypotha-larnic brain: non-identity with synthetic pyroGlu-His-ProNH2 (TRH). Brain Res. (1978) 151:99–116.
   PubMed Web of Science ®Google Scholar
• ZAHN V: Physiologie der Uteruskontralctionen. Z. Ge-buns. Perinat (1978) 182:263–267.
   Google Scholar
• First publication dealing with physiologic uterine motility during pregnancy
   Google Scholar
• ZAMKOFF K, NEWMAN N, PAOLOZZI F, RUDOLPH A, BRADLEY E, DOYLE M, KONRAD M, KIRSCHNER J, SZALZO A, DIFINO S, GULLO J, POIESZ B: A phase I study of recombinant interleukht-2 and recombinant 13-inter-feron in patients with advanced malignancy. Proc. Am. Assoc. Cancer Res. (1987) 6:242,
   Google Scholar
• ZHAN X, CULPEPPER A, REDDY M, LOVELESS.J, GOLDFARB M: Human oncogenes detected by a defined medium culture assay. Oncogenes (1987) 1:369–376.
   PubMed Web of Science ®Google Scholar
• ZHAU FEE, ZHANG X, VON ESCHENGACH AC, SCORSONE K, BABAIAN RJ, RO JY, HUNG MC: Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. Mol. CarcM. (1990) 3:254–257.
   PubMed Web of Science ®Google Scholar
• ZHOU DJ, CASEY G, CLINE MJ: Amplification of human int-2 in breast cancers and squantous carcinomas. On-cogene (1988) 2:279–282.
   Google Scholar
• ZIEGLER LD, PALAZZOLO P, CUNNINGHAM J, JANUS M, ITOH K, HAYAKAWA K, MURRAY JL: Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of breast, colorectal, and lung. J. Clin. Oncol. (1992) 10:1470–1478.
   PubMed Web of Science ®Google Scholar
• ZIMMER A: Einmalapplikation, Mehrfachapplikation und Metabolitenmuster von Clenbuterol bei Menschen.Arzn. Forsch./Drug Res. (1976) 26:1446–1450.
   PubMedGoogle Scholar
• ZUCKERMAN H, SHALEV E, GILAD G, KATZUNI E: Further study of the inhibition of premature labor by in-domethacin. Part IL Double blind study. J. Perinat. Med. (1984) 12:25-29.[41] and 1421 are the first studies dealing with the possibilities of indomethacin as a prostaglandin synthesis inhibitor for tocolytic therapy.
   Google Scholar